GUIDELINES

Guidelines for surgical treatment of gastroesophageal reflux disease

**Dimitrios Stefanidis · William W. Hope · Geoffrey P. Kohn · Patrick R. Reardon ·
William S. Richardson · Robert D. Fanelli · The SAGES Guidelines Committee**

Preamble

The guidelines for the surgical treatment of gastroesophageal reflux disease (GERD) are a series of systematically developed statements to assist physicians and patient decisions about the appropriate use of laparoscopic surgery for GERD. The statements included in this guideline are the product of a systematic review of published literature on the topic, and the recommendations are explicitly linked to the supporting evidence. The strengths and weaknesses of the available evidence are highlighted and expert opinion sought where the evidence is lacking. This is an update of previous guidelines on this topic (last revision 06/2001) as new information has accumulated.

D. Stefanidis (✉)
Division of Gastrointestinal and Minimally Invasive Surgery,
Carolinas Medical Center, Charlotte, NC, USA
e-mail: dimitrios.stefanidis@carolinashealthcare.org

W. W. Hope
Department of Surgery, New Hanover Regional Medical Center,
Wilmington, NC, USA

G. P. Kohn
Department of Surgery, Maroondah Hospital, Monash
University, Melbourne, Australia

P. R. Reardon
Department of Surgery, The Methodist Hospital, Houston, USA

W. S. Richardson
Department of Surgery, Ochsner Clinic Foundation,
Jefferson, USA

R. D. Fanelli
Surgical Specialists of Western New England,
PC, Pittsfield, USA
e-mail: rfanemd@massmed.org

Disclaimer

Guidelines for clinical practice are intended to indicate preferable approaches to medical problems as established by experts in the field. These recommendations will be based on existing data or a consensus of expert opinion when little or no data are available. Guidelines are applicable to all physicians who address the clinical problem(s) without regard to specialty training or interests, and are intended to indicate the preferable, but not necessarily the only, acceptable approaches due to the complexity of the healthcare environment. Guidelines are intended to be flexible. Given the wide range of specifics in any health care problem, the surgeon must always choose the course best suited to the individual patient and the variables in existence at the moment of decision.

Guidelines are developed under the auspices of the Society of American Gastrointestinal and Endoscopic Surgeons and its various committees, and approved by the Board of Governors. Each clinical practice guideline has been systematically researched, reviewed, and revised by the guidelines committee, and reviewed by an appropriate multidisciplinary team. The recommendations are therefore considered valid at the time of its production based on the data available. Each guideline is scheduled for periodic review to allow incorporation of pertinent new developments in medical research knowledge, and practice.

Literature review method

A large body of literature on the surgical treatment of GERD exists. A systematic literature search was performed on MEDLINE in March 2008. The search strategy was limited to adult, English-language articles and is shown in Appendices 1 and 2.

We identified 448 relevant articles. The abstracts were reviewed by four committee members (D.S., W.W.H., P.R.R., G.P.K.) and divided into the following categories:

(a) Randomized studies, metaanalyses, and systematic reviews
(b) Prospective studies
(c) Retrospective studies
(d) Case reports
(e) Review articles

Randomized controlled trials, metaanalyses, and systematic reviews were selected for further review, along with prospective and retrospective studies that included at least 50 patients. Studies with smaller samples were considered when additional evidence was lacking. The most recent reviews were also included. All case reports, older reviews, and smaller studies were excluded. According to these exclusion criteria, 227 articles were reviewed. Whenever the available evidence from level I studies was considered to be adequate, lower evidence level studies were not considered. A review of the available evidence on endoluminal treatment of GERD has recently been published by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) in April 2009.

The reviewers graded the level of evidence and manually searched the bibliography of each article for additional articles that may have been missed during the original search. The additional relevant articles ($n = 66$) found were also included in the review. A total of 293 graded articles relevant to this guideline were reviewed. To facilitate review by multiple reviewers, these articles were divided into the following topics:

(a) Fundoplication versus medical treatment
(b) Laparoscopic versus open fundoplication
(c) Partial versus full fundoplication or partial versus partial
(d) Other technique
(e) Revisions
(f) Outcome
(g) Predictors of success
(h) Other articles

The recommendations included in this guideline were devised based on the reviewers' grading of all articles.

Levels of evidence

Level I: Evidence from properly conducted randomized, controlled trials
Level II: Evidence from controlled trials without randomization, or cohort or case–control studies, or multiple time series dramatic uncontrolled experiments
Level III: Descriptive case series, opinions of expert panels

Limitations of the available literature

Despite the availability of several randomized controlled trials and metaanalyses, most available studies are either prospective or retrospective reports. Several limitations exist in the examined literature. First, the general methodological quality of the available trials is low due to small patient numbers, inadequate trial design or methodology, lack of standardization, and lack of objective outcome assessment [1]. Only a few studies report a power analysis and define a main outcome variable. Thus, the validity of several of the pooled analyses of the available metaanalyses is hampered by statistically significant heterogeneity related to small sample size. In addition, the reporting of outcomes varies significantly, as does the follow-up period, making it difficult to combine and compare such data. Furthermore, there are several differences in the surgical technique used that may directly impact the outcomes of interest and introduce bias into the reported outcomes. Finally, the majority of the studies do not report details on the expertise of their surgeons, and most have been conducted in single institutions, making generalization of their findings difficult.

Introduction

GERD has long been recognized as a significant public health concern. Heartburn afflicts nearly two-thirds of US adults at some point in their lives [2], and accounts for 4–5 million physician office visits every year [3]. This document outlines the indications for and surgical treatment of GERD. This document is not intended to debate the issues of medical or endoscopic management of GERD, which are well described in prior publications [4, 5].

Definition

GERD was defined according to the Montreal Consensus as "a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications." Symptoms were considered "troublesome" if they adversely affected an individual's well-being [5].

From a surgical perspective, GERD is the failure of the antireflux barrier, allowing abnormal reflux of gastric contents into the esophagus [6]. It is a mechanical disorder, which is caused by a defective lower esophageal sphincter (LES), a gastric emptying disorder, or failed esophageal peristalsis. These abnormalities result in a spectrum of disease, ranging from symptoms only, such as "heartburn," to esophageal tissue damage with or without subsequent complications including malignancy or airway disease.

While the exact nature of the antireflux barrier is incompletely understood, the current view is that the LES, the diaphragmatic crura, and the phrenoesophageal ligament are key components [7, 8].

Diagnosis

Before considering surgery, objective documentation of gastroesophageal reflux is mandatory. This can often be achieved by flexible esophagoscopy. Endoscopic visualization of any "mucosal break," defined as an area of slough or erythema clearly demarcated from adjacent normal-appearing mucosa [9], is considered objective proof of GERD in the appropriate clinical setting. This mucosal break is the minimum endoscopic lesion that is a reliable indicator of reflux esophagitis [10].

In an appropriate setting, a peptic stricture is also acceptable evidence of GERD [11], as long as malignancy has been ruled out by multiple biopsies. Histological proof of Barrett's esophagus is currently also considered objective evidence of GERD, even though other very rare causes of Barrett's esophagus may also exist [12, 13].

In the absence of endoscopic evidence of reflux, the current gold-standard objective test to diagnose gastroesophageal reflux is 24-h ambulatory esophageal pH-metry. The variables with the highest sensitivity and specificity which are obtained from this test are: total time with pH < 4 as recorded by a probe placed 5 cm above the LES, and a composite score (comprised of the following six variables: total esophageal acid exposure time, upright acid exposure time, supine acid exposure time, number of episodes of reflux, number of reflux episodes lasting more than 5 min, and duration of the longest reflux episode) [14]. An alternative diagnostic modality to 24-h catheter-based pH-metry is the 48-h wireless esophageal pH-monitoring probe (Bravo™; Medtronic, Shoreview, MN). The Bravo probe is considered equivalent to the catheter-based system, but no additional benefit has been realized by prolonging the study period to 48 h [15, 16].

A newer test to objectively document gastroesophageal reflux is multichannel intraluminal esophageal impedance, but the available evidence is insufficient to provide firm recommendations [17].

Recommendation

Based on the available evidence, diagnosis of GERD can be confirmed if at least one of the following conditions exists: a mucosal break seen on endoscopy in a patient with typical symptoms, Barrett's esophagus on biopsy, a peptic stricture in the absence of malignancy, or positive pH-metry (grade A).

Indications for surgery

When the diagnosis of reflux is objectively confirmed, surgical therapy should be considered in individuals who:

1. Have failed medical management (inadequate symptom control, severe regurgitation not controlled with acid suppression, or medication side-effects)

OR

2. Opt for surgery despite successful medical management (due to quality-of-life considerations, lifelong need for medication intake, expense of medications, etc.)

OR

3. Have complications of GERD (e.g., Barrett's esophagus, peptic stricture) [18, 19]

OR

4. Have extra-esophageal manifestations (asthma, hoarseness, cough, chest pain, aspiration) [20–23]

Coexistence of Barrett's esophagus with gastroesophageal reflux symptoms is considered by many a clear indication for antireflux surgery [24]. Surgical intervention for asymptomatic Barrett's esophagus is more controversial, however. While the metaplastic changes of Barrett's have been reported to regress to a greater degree in the postsurgical population compared with medically treated patients, to date there is no demonstrable improvement in esophageal adenocarcinoma rates [25, 26].

Preoperative workup

The aim of preoperative investigations is to select reflux patients appropriate for surgical treatment to optimize outcomes. There is currently no consensus, and significant variability, among surgeons regarding which studies should be obtained before surgery, and in what order.

1. Esophagogastroduodenoscopy (EGD): Is likely the one study that all patients should have preoperatively, as it can confirm the diagnosis of GERD or identify other etiologies of esophagogastric mucosal abnormalities and allows biopsies to be taken.
2. pH-metry: Important for patients when the diagnosis of GERD cannot be confirmed on EGD or diagnostic uncertainty exists. A normal 24-h intraesophageal pH study after an H2-blocker- and proton pump inhibitor (PPI)-free interval should strongly suggest an alternate diagnosis and lead to additional diagnostic investigations.

3. Esophageal manometry: Frequently performed before surgery and advocated by many experts in order to identify conditions that might contraindicate fundoplication (such as achalasia) or modify the type of fundoplication according to a tailored approach based on esophageal motility. Nevertheless, there is no support in the literature for mandatory preoperative manometry [27–29], and there are numerous studies refuting the need for a tailored approach to fundoplication.

4. Barium swallow: Frequently obtained test for better delineation of the anatomy. May be particularly valuable in patients with large hiatal hernias who have a shortened esophagus.

Other preoperative tests have been examined, such as gastric emptying studies [30], but there are no data to support a correlation between their results and postoperative outcomes. This test may be important, however, in patients who require reoperation, as it may provide indirect evidence for vagal nerve injury during the original surgery.

Medical versus surgical treatment

To date, seven randomized controlled trials with follow-up of these studies ranging from 1 to 10.6 years have compared surgical therapy with medical therapy for the treatment of GERD [31–37]. These studies strongly support surgery as an effective alternative to medical therapy [32–37] (level I) both for patients with good symptom control on medical therapy [32–37] and for those who achieve only partial symptomatic relief from PPIs [34] (level I).

The majority of available studies also provide convincing objective evidence for the effectiveness of surgery. Based on pH-metry and manometric data, fundoplication results in significantly less acid exposure and significantly increased LES pressure compared with medical therapy [32, 33, 38–40] (level I–III). The one level I study that failed to demonstrate differences in the duration of acid exposure was underpowered [31].

Fundoplication has also been demonstrated to lead to improved or at least comparable quality of life to that of medically treated patients and is associated with high patient satisfaction rates [32, 33, 35, 36, 39] (level I–III). One study reported no difference or worse quality of life of postfundoplication patients if they were not taking acid-reducing medications postoperatively [31] (level I).

Regarding acid-reducing medication, one level I evidence study reported it to be used in up to 62% of postfundoplication patients postoperatively [31] (level I), whereas the majority of the available literature cites a much lower incidence (9–21%) up to 8 years after surgery [34, 41–45] (level I–III). Importantly, several studies have demonstrated that most patients who resume acid-reducing medications postoperatively have no objective evidence for GERD recurrence on 24-h pH studies [46, 47] (level II).

There has been one randomized controlled trial evaluating cost between medical (omeprazole) and surgical therapy (open total and partial fundoplication) over a 5-year period [48]. The study reported that total treatment costs in the medical group were significantly lower than for antireflux surgery in three European countries (Denmark, Norway, and Sweden) and higher in one (Finland) [48] (level I). One modeling study found that the cost-equivalency point for medical and surgical therapy was at 10 years [49], whereas another still reported lower cost with medical therapy at 10 years [50] (level III).

Recommendations

Surgical therapy for GERD is an equally effective alternative to medical therapy and should be offered to appropriately selected patients by appropriately skilled surgeons (grade A). Surgical therapy effectively addresses the mechanical issues associated with the disease and results in long-term patient satisfaction (grade A). For surgery to compete with medical treatment, it has to be associated with minimal morbidity and cost.

Surgical technique, learning curves, and their influence on outcome

While the choice of technique for antireflux surgery has traditionally been based on anatomic considerations and the surgeon's preference and expertise, this approach has been criticized in the literature, as the lack of standardization makes outcome comparisons difficult. Recently, a randomized trial designed to compare medical and surgical therapy managed to standardize the Nissen fundoplication technique across several institutions and surgeons [51]. Based on a consensus of 40 experienced foregut surgeons, the following standardized approach to Nissen fundoplication was followed: (a) opening of the phrenoesophageal ligament in a left-to-right fashion, (b) preservation of the hepatic branch of the anterior vagus nerve, (c) dissection of both crura, (d) transhiatal mobilization to allow approximately 3 cm of intraabdominal esophagus, (e) short gastric vessel division to ensure a tension-free wrap, (f) crural closure posteriorly with nonabsorbable sutures, (g) creation of a 1.5–2 cm wrap with the most distal suture incorporating the anterior muscular wall of the esophagus, and (h) bougie placement at time of wrap construction [51]. This standardization led to excellent postoperative outcomes comparable to medical treatment and included a 2% conversion rate, 3% postoperative complication rate, and median postoperative length of stay of 2 days [51] (level I).

The learning curve for laparoscopic antireflux surgery has been well documented in the literature, with reports of increased failure rates [52], complications [53], reoperations [53], operative time [54], hospital days [54], and conversions to open surgery [53, 54] (level III) by less experienced surgeons. To minimize adverse outcomes as a result of the learning curve, studies have suggested that surgeons seek experienced supervision during their first 15–20 laparoscopic antireflux procedures [53] (level III). Nevertheless, good results have been reported by young surgeons after appropriate training in laparoscopic surgery [55, 56] (level II–III). The literature also suggests that reoperative antireflux surgery should be undertaken in high-volume tertiary centers by experienced antireflux surgeons, citing a decreased conversion rate compared with lower-volume centers [57] (level II).

Recommendations

The standardization of antireflux surgery technique is highly desirable, as it has been shown to lead to good postoperative patient outcomes (grade A). Like any other surgical procedure, laparoscopic antireflux surgery is subject to a learning curve, which may impact patient outcomes. Therefore, surgeons with little experience in advanced laparoscopic techniques and fundoplication in particular should have expert supervision during their early experience with the procedure to minimize morbidity and improve patient outcomes (grade B). On the other hand, reoperative antireflux surgery should be performed in a high-volume center by an experienced foregut surgeon (grade B).

Laparoscopic versus open treatment of GERD

To date, 12 randomized controlled trials and two metaanalyses have compared the results of open with laparoscopic fundoplication [58–78]. All but one of these trials compared open with laparoscopic Nissen fundoplication with some technical variations.

Regarding immediate perioperative results, no study reported any mortality. In the most recent metaanalysis, perioperative morbidity was found to be significantly lower (65%) after laparoscopic compared with open fundoplication [75] (level I).

The conversion rate to open surgery varied between 0% and 9.6%, with the most recent randomized controlled trial reporting lower conversion rates (<5%). Laparoscopic surgery was associated with longer operative duration (approximately 40 min) but also with significant reductions in hospital stay (2.68 days) and in return to normal activity (7.75 days) compared with the open approach [75] (level I).

The two approaches have been demonstrated to have similar postoperative outcomes at the reported follow-up intervals (range 3–24 months) including reflux recurrence, dysphagia, bloating, and reoperation rates [59] (level I).

Nevertheless, the most recent metaanalysis found a higher requirement for further surgery in the laparoscopic group even though treatment failures between the two techniques were comparable [75] (level I). Interestingly one randomized controlled trial that had shown significantly higher rates of reoperation after laparoscopic Nissen compared with open Nissen in the short term [58] did not find similar differences 5 years later [62] (level I). In another recent randomized controlled trial, the reoperation rate was similar; however, reoperation in the laparoscopic Toupet group was due to continued heartburn, and it was due to incisional hernias in the open Toupet group [64] (level I).

Randomized studies investigating the immune system demonstrated significantly reduced white blood cells counts and serum C-reactive protein levels after laparoscopic fundoplication but no significant differences in serum cortisol levels, indicative of the less invasive nature of the laparoscopic procedure [70, 74, 79, 80] (level I).

Recommendations

Based on the available evidence that is of high quality (level I), laparoscopic fundoplication should be preferred over its open alternative as it is associated with superior early outcomes (shorter hospital stay and return to normal activities, and fewer complications) and no significant differences in late outcomes (failure rates) (grade A). Nevertheless, antireflux surgeons should be aware that laparoscopic fundoplication takes longer to perform and has a higher incidence of reoperations, at least in the short term (grade A). Further study is needed to identify ways to minimize the incidence of reoperations after laparoscopic fundoplication.

Partial versus total fundoplication

Eleven randomized controlled trials and two metaanalyses have investigated the differences between partial and total fundoplications, and one randomized controlled trial between two partial fundoplications [1, 27, 59, 76, 81–94] (level I).

A single perioperative death, for an incidence of 0.07% across all these studies, has been reported. This death was a consequence of esophageal injury resulting in mediastinitis. No differences in perioperative morbidity were found across all published studies by the two published metaanalyses [1, 59] (level I). In addition, no differences in length of the operative procedure between partial (independent of type) and total fundoplication have been reported, with an average duration across studies of approximately 90 min.

Regarding specific postoperative patient outcomes, a significantly higher incidence of postoperative dysphagia, bloating, flatulence, and reoperation rate has been found for total compared with partial fundoplication [1] (level I).

On the other hand, no significant differences between the two types of procedures were noted in incidence of esophagitis, heartburn, and persisting acid reflux, the proportion of patients experiencing good or excellent long-term outcome, or the proportion of patients with Visick I or II score [1] (level I). Interestingly, the notion that the type of fundoplication should be tailored to esophageal motility [95, 96] (level III) has been challenged by several studies. The available evidence suggests that the outcomes of patients with esophageal dysmotility are not affected by the type of fundoplication [94, 97] (level I).

Since there is significant inhomogeneity in the type of partial fundoplication evaluated in the available randomized controlled trials, we also report outcomes in three different categories: anterior versus total, posterior versus total, and anterior versus posterior fundoplication.

Anterior versus Nissen fundoplication

Four randomized controlled trials reporting on 457 patients with follow-up ranging from 6 months to 10 years have been published [81, 88, 90, 98–100] (level I) comparing laparoscopic anterior fundoplication with laparoscopic Nissen fundoplication. Two studies included 180° and the other two 90° anterior fundoplication. Based on the findings of these trials, anterior fundoplication was associated with significantly less postoperative dysphagia according to at least one of the evaluated dysphagia parameters compared with the Nissen fundoplication even during long-term follow-up (up to 10 years) [98] (level I). On the other hand, anterior fundoplication was found to be less effective for reflux control (based on patient symptoms and objective tests), as more patients required reoperations for reflux control [90] (level I). Patient satisfaction ratings were similar between the groups in all studies up to 10 years after surgery [98] (level I). Whether there are differences between 90° and 180° fundoplication is unclear, as no comparative studies exist; however, Engstrom et al. have suggested that 90° fundoplication is inadequate [101] (level I).

Toupet versus Nissen fundoplication

Nine randomized controlled trials (including both open and laparoscopic techniques) with follow-up of 1–5 years have compared Toupet with Nissen fundoplication [27, 82, 83, 85, 86, 91–94, 97, 102, 103] (level I). The majority of published studies have demonstrated lower dysphagia rates after Toupet fundoplication and no difference in heartburn control between the two procedures at follow-up (level I). In addition, no differences have been demonstrated for any of the other outcome parameters. Interestingly, a very recent study that compared variable lengths of fundoplication (1.5 cm versus 3 cm) for both procedures demonstrated that

the 3-cm Toupet achieved superior reflux control over the 1.5-cm Toupet without differences in postoperative dysphagia. The Nissen fundoplication length did not influence reflux control, but a trend for a higher dysphagia rate was noted with the 3-cm wrap compared with the 1.5-cm wrap at the 12-month follow-up of this study [102] (level I). Longer follow-up data are needed to confirm the long-term comparative effectiveness between Toupet and Nissen fundoplication, as the current level I evidence does not go beyond 5 years. This is especially important because retrospective studies suggest inferior long-term reflux control after Toupet [104, 105] (level III).

Anterior versus Toupet fundoplication

One randomized controlled trial has compared two partial fundoplications: 120° anterior and 180–200° posterior [101, 106] (level I). This study followed 95 patients for 5 years (93% follow-up) and found that posterior fundoplication was superior to the anterior by achieving better reflux control without increased incidence of postoperative dysphagia. In addition, this study demonstrated statistically significantly higher PPI intake, more esophageal acid exposure, higher reoperation rates, and lower patient satisfaction after anterior fundoplication during long-term follow-up and concluded that anterior repair cannot be recommended for GERD due to insufficient reflux control [101] (level I).

Recommendations

Based on the available evidence that is of high quality (level I), partial fundoplication is associated with less postoperative dysphagia, fewer reoperations, and similar patient satisfaction and effectiveness in controlling GERD compared with total fundoplication up to 5 years after surgery (grade A). Furthermore, a tailored approach to esophageal motility appears unwarranted (grade B). Nevertheless, the paucity of long-term follow-up data that compare the effectiveness of the procedures makes it hard to recommend one type of fundoplication over the other, especially in an era when the long-term effectiveness of surgical treatment for GERD is questioned. It should also be noted that a body of literature suggests that anterior partial fundoplication may be less effective in the long term (grade B), and retrospective data suggest that partial fundoplication may not be as effective as total in the long run (grade C). Nonetheless, the evidence suggests that surgeons appropriately trained in minimally invasive techniques who perform surgery for GERD may minimize postoperative dysphagia by choosing partial fundoplication (grade A) or short total fundoplication (1–2 cm) over a large bougie (56 French) (grade C) and maximize the effectiveness of the procedure by choosing total fundoplication (grade C) or longer (at least 3 cm) posterior fundoplication (grade C). It should also be noted that there are regional differences in expert opinion and practice in the choice of fundoplication type for GERD, with most North American experts choosing total fundoplication due to concerns for the long-term effectiveness of the procedure. Controlled studies that take into account these guidelines are needed.

Other technical aspects that may influence outcomes

The following technical issues and patient factors may influence the outcome of fundoplication and are discussed separately:

Short gastric vessel division

Five randomized controlled trials have evaluated the impact of short gastric vessel division on outcomes following laparoscopic antireflux surgery. Evidence from these high-quality studies suggests no difference in physiologic, symptomatic, and quality of life outcomes up to 10 years after surgery [107–111] (level I). Furthermore, division of short gastric vessels at time of fundoplication has been found to increase operating time [107, 110–112] (level I–II), increase flatus production and epigastric bloating, and decrease ability to vent air from the stomach [108, 109, 111] (level I). However, it must be mentioned that a previous review based on the data from all but the most recent randomized controlled trial gave a low-grade recommendation due to the inconsistency of results [113], and expert opinion in North America advocates routine division.

Recommendations

When the fundus can be wrapped around the esophagus without significant tension, no division of the short gastrics seems necessary (grade A). Division should be undertaken when a tension-free fundoplication cannot be accomplished (grade B). It should also be noted that expert opinion in North America advocates routine division of the short gastric vessels to minimize tension (grade C).

Crural closure

There have been no randomized controlled trials comparing closure with no closure of the crura. Individual reports stress the benefits of posterior crural repair for satisfactory outcomes [114–116], but others report no difference in outcomes [27, 110, 117–119]. Several authors have reported selective crural closure based on the size of the hiatal opening, but no clinical comparisons exist [38, 40, 43, 45, 120–125]. One study recommended division of the short gastric vessels, posterior closure of the crura, and fixation of the wrap to the crus, demonstrating significantly decreased incidence of wrap slippage and need for secondary intervention when following this approach [116] (level III). One randomized controlled trial compared the efficacy of anterior with posterior crural repair and reported no difference between the anterior or posterior closure groups in terms of postoperative dysphagia, heartburn, and overall satisfaction at 6-month follow-up. To achieve a similar dysphagia rate, however, more patients in the posterior closure group had to undergo a second surgical procedure [119] (level I).

Other potential technical factors that may reduce the incidence of wrap migration related to crural closure have also been evaluated. The use of prosthetic mesh as a buttress to posterior crural closure has been reported to significantly decrease intrathoracic wrap migration [126] (level I), with one report recommending tailoring the type of crural closure, suture alone, mesh buttress, or tension-free mesh closure, based on the size of the hiatal surface area [127] (level II).

Minimal esophageal dissection techniques have also been proposed and reported as an acceptable method for fundoplication [123] (level II), with reports of decreased wrap transmigration in the pediatric population related to this technique [128] (level III). Nevertheless, expert opinion suggests that, in the case of a short esophagus, more extensive mediastinal mobilization is needed to increase the segment of intraabdominal esophagus (at least 2–3 cm) and thus decrease the chance of herniation (level III).

Recommendations

Crural closure should be strongly considered during fundoplication when the hiatal opening is large, and mesh reinforcement may be beneficial in decreasing the incidence of wrap herniation (grade B). Anterior crural closure may be associated with less postoperative dysphagia, but additional evidence is needed to provide a firm recommendation (grade C).

Use of robotic surgery

The use of robotic surgery has been reported to be safe and feasible with similar outcomes during up to 1-year follow-up compared with laparoscopic antireflux surgery [125, 129–133] (level I–II). Most of the five available randomized controlled trials have reported a significant increase in operating times and cost when the robot is used [125, 132, 133] (level I). Unfortunately, there are no clinical data comparing ergonomics and surgeon workload between these two approaches; however, level I data from simulator studies have shown less surgeon workload with the use of the robot [134].

Recommendation

While robotic assistance can be safely and effectively used for fundoplication, its higher cost compared with conventional laparoscopy and similar short-term patient outcomes make it a less than ideal initial choice (grade B). Nevertheless, further study regarding learning curves and surgeon workload with the robotic technique are needed before stronger recommendations can be made.

Antireflux surgery in the morbidly obese patient

There is a clear association between GERD and morbid obesity, with the disease being more prevalent as body mass index (BMI) increases [135–142]. The long-term effectiveness of fundoplication in obese individuals (BMI > 30kg/m^2) has been questioned due to higher failure rates [143, 144] (level II–III) compared with normal-weight patients. Nevertheless, others have reported equivalent outcomes in obese and normal-weight individuals [145–148] (level II–III). Laparoscopic Roux-en-Y gastric bypass (LRYGB) is the most effective and advantageous treatment option for GERD in the morbidly obese patient [149, 150], since it treats GERD effectively and provides the additional benefit of weight loss and improvement in comorbidities, and is therefore the procedure of choice by many experts [151–156] (level II–III). Laparoscopic Roux-en-Y gastric bypass has also been reported to be a feasible and efficacious treatment in morbidly obese patients who have previously undergone laparoscopic antireflux surgery, although it is technically demanding and has a higher morbidity [157] (level III). While adjustable gastric banding may also improve GERD symptoms, conflicting reports exist, and it is therefore not the procedure of choice for this indication [137, 158–161].

Recommendation

Due to concerns for higher failure rates after fundoplication in the morbidly obese patient (BMI > 35 kg/m^2) and the inability of fundoplication to address the underlying problem (obesity) and its associated comorbidities, gastric bypass should be the procedure of choice when treating GERD in this patient group (grade B). The benefits in patients with BMI > 30 kg/m^2 are less clear and need further study.

Use of esophageal dilators

Level I evidence suggests that use of an esophageal dilator decreases the long-term incidence of dysphagia [162]. The only available randomized controlled trial reported a significant decrease in the postoperative dysphasia rate at 11-month follow-up in patients who had a 56-French bougie placed at time of surgery versus patients who did not have a bougie placed, and there was no difference in perioperative morbidity and mortality [162] (level I). There was, however, a 1.2% incidence of esophageal injury due to placement of the bougie [162] (level I).

Recommendations

The placement of an esophageal dilator during the creation of laparoscopic fundoplication is advisable as it leads to decreased postoperative dysphagia but should be weighed against a small risk of esophageal injury (grade B). A 56-French bougie has been found to be effective, but the evidence is limited (grade C).

Predictors of success

Preoperative patient compliance with antireflux medications [163]

One study examined the predictive value of self-reported preoperative compliance with medical treatment. Patients compliant with their preoperative medical treatment of GERD with PPI showed a statistically significantly larger improvement in the postoperative gastrointestinal quality of life index than patients who were noncompliant preoperatively. In addition, noncompliant patients had higher rates of postfundoplication dysphagia at 1-year follow-up.

Age

Age has not been found to significantly affect the outcomes of antireflux surgery. Besides a tendency for longer postoperative hospitalization, patients >65 years of age can expect an excellent outcome after surgery in at least 90% of cases, similar to younger patients [164].

Postoperative "diaphragmatic stressors"

Sudden increases in intra-abdominal pressure in the early postoperative period are thought to predispose a patient to anatomical failure of fundoplication. One study has suggested that early postoperative gagging, belching, and vomiting (especially when associated with gagging) are predisposing factors for anatomical failure and the need for revision [165] (level III). In addition, hiatal hernias >3 cm at original operation have been reported to be predictors for anatomic failure (level II).

Psychological disease and intervention

While major depression has not been shown to influence objective physiologic outcomes of fundoplication, it appears to impact postoperative quality of life. In particular, quality-of-life scores have been shown to improve postoperatively in depressed patients but to a lesser extent than in healthy subjects. In addition, severe postoperative dysphagia and severe bloating were found to be statistically significantly more common in patients with major depression compared with healthy controls [166] (level II). One study concluded that 270° partial fundoplication had better outcomes in patients with major depression compared with 360° fundoplication due to a lower incidence of postoperative dysphagia and gas bloat syndrome [166] (level II).

Cognitive behavioral therapy in the postoperative period has been shown to improve dysphagia and gastrointestinal symptoms such as flatulence and abdominal pain in

patients with a preoperative diagnosis of anxiety [167] (level I).

Atypical symptoms

Patients with atypical symptoms of GERD, such as chest pain, asthma, chronic cough, hoarseness, otitis media, atypical loss of dental enamel, idiopathic pulmonary fibrosis, recurrent pneumonia, and chronic bronchitis [168], are known to respond less well to fundoplication compared with patients with typical symptoms (heartburn and regurgitation) [169] (level II). For this reason, several investigators have sought ways to preoperatively predict the success of fundoplication performed for atypical symptoms. Of the factors examined, the best predictors have been found to be good symptom correlation with reflux episodes during combined esophageal multichannel intraluminal impedance and pH monitoring [170] (level II), and a positive Bernstein esophageal acid infusion test [171] (level II).

Esophageal function

Normal LES pressure on manometry has not been shown to be associated with increased rates of postoperative dysphagia [172, 173] (level II). Patients with nonspecific spastic esophageal motor disorders (such as nutcracker esophagus, hypertensive LES syndrome) have been reported to be at increased risk for postoperative heartburn, regurgitation, and dysphagia after 360° wrap [174] (level II).

Patterns of reflux

Patients with upright reflux are thought to have more maladaptive behaviors associated with their reflux, including aerophagia, regurgitation, and dyspepsia, compared with patients who experience typical reflux when supine [175]. Nevertheless, with the exception of one study that suggested that patients with upright reflux have an increased rate of gas bloat syndrome postoperatively [176], the preponderance of evidence suggests that laparoscopic Nissen fundoplication is equally effective regardless of the pattern of reflux [30, 175] (level II).

Response to preoperative PPI

Symptomatic response to preoperative PPI treatment has been shown to be an excellent predictor of symptomatic response to fundoplication. One study found that patients with no response to preoperative PPI administration had lower satisfaction rates after fundoplication compared with patients who had at least a partial response [143] (level II).

However, nonresponse to PPI is not considered a contra-indication to antireflux surgery [177], as studies have demonstrated very good success rates in these patients (level II).

Preoperative gastric emptying

It has been suggested that delayed gastric emptying may affect postoperative gastric distension and overall surgical outcomes. However, one large prospective nonrandomized trial showed no relationship between gastric emptying and outcome following fundoplication [30] (level II).

Recommendations

1. Surgeons should be aware that fundoplication in patients demonstrating poor compliance with PPI therapy preoperatively or with poor response to preoperative PPI treatment is associated with poorer outcomes (grade C).
2. Age should not be considered a contraindication for antireflux surgery in otherwise acceptable operative candidates, as outcomes in this patient group are similar to outcomes of younger patients (grade C).
3. Care should be taken to minimize early postoperative severe gagging, belching, and vomiting as weak evidence suggests that they may lead to anatomical failure of fundoplication (grade C).
4. Partial wrap should be considered in patients with a preoperative diagnosis of major depression, as it may lead to better postfundoplication outcomes in this patient group that tends to have generally inferior outcomes (grade C).

Revisional surgery for failed antireflux procedures

Most authors recommend the same surgical approach for the reoperative patient as for the primary procedure [2, 178–181] (level III). Multiple retrospective studies have evaluated the short- and long-term outcomes of revisional laparoscopic antireflux surgery with up to 12-year follow-up. Compared with primary repair, revisional surgery requires longer operative times and is associated with higher conversion rates to open surgery [179, 182] (level III) and higher complication rates (30-day mortality <1%, esophagogastric perforations in 11–25% [179, 183], gastric more often than esophageal perforation [180], pneumo-thorax in 7–18% [180, 184], splenic injuries in 2% [185], and vagal nerve injuries in 7% [179, 180]). Nevertheless, postoperative dysphagia (3–17%) [179, 184–187] and gas bloat syndrome (5–34%) do not seem to be significantly higher after reoperation compared with primary repair. Patient satisfaction after reoperative laparoscopic antireflux surgery has been reported to be high (89%) [185] with resolution of heartburn symptoms in 68–89% of patients [186] and resolution of regurgitation in 83–88% [2, 181, 185] up to 18 months after revisional surgery.

Nevertheless, up to 13% of patients may experience reflux recurrence at 3-month follow-up based on objective testing [187].

Recommendation

Laparoscopic reoperative antireflux surgery is feasible, safe, and effective but has higher complication rates compared with primary repair and should be undertaken only by experienced surgeons using a similar approach to primary fundoplication (grade B).

Outcomes

Laparoscopic antireflux surgery has proven to be a safe, effective, and durable treatment option for GERD (level I–III). Multiple studies have evaluated the short- and long-term outcomes of laparoscopic antireflux surgery with follow-up ranging up to 11 years [143, 188].

Response of typical GERD symptoms to antireflux surgery

Typical symptoms of gastrointestinal reflux disease improve in the majority of patients after surgery during short-term [32, 36, 39, 42, 189–198] (level I–III) and long-term (>5 years) follow-up [31, 36, 37, 41, 42, 44, 47, 107, 109, 188, 199] (level I–III). Nevertheless, symptom control may wane over time, as studies [36] with shorter follow-up periods (3 years) report, in general, better symptom resolution (90%) than studies with longer-term follow-up (67% of patients at 7-year follow-up [31, 37]) (level I). Improvements have also been demonstrated for patients with Barrett's esophagus [200], elderly patients [195], and patients with and without preoperative esophagitis [201].

Following laparoscopic antireflux surgery, dysphagia has been reported to significantly improve from preoperative values [47, 188, 197, 198, 200–204] (level II–III). Despite reports of improved dysphagia following surgery, postoperative dysphagia remains a significant problem, with reported reoperation rates ranging from 1.8 to 10.8% [33, 34, 38, 39, 143, 196, 205–207] (level I–III) and endoscopic dilatation rates ranging from 0 to 25% [34, 121, 143, 145, 189, 195, 196, 208–213] (level I–III). Although perioperative and early postoperative dysphagia have been reported as high as 76% [191] (level II), the majority of studies show early and mid dysphagia rates, up to 1 year postoperatively, of less than 20% [33, 34, 38, 39, 44, 47, 120, 122, 189, 191, 192, 195, 196, 199, 200, 209, 210, 212, 214–221] (level I–III) and long-term rates around 5–8% [45, 109, 207, 222] (level I–II).

Likewise, significant improvement in heartburn symptoms has been reported following laparoscopic antireflux surgery [47, 109, 110, 143, 188, 190, 193, 197, 198, 200–204, 209, 215, 221, 223, 224] (level I–III) with recurrence rates of ≤10% in the majority of studies [41, 47, 120, 143, 190, 196, 199, 203, 213, 215–217, 221, 225, 226] (level II–III). Regurgitation rates have also shown to be significantly improved following surgery, with improvement rates of 87–97% reported [109, 143, 188, 190, 195, 198, 202, 203, 227] (level I–III). Although recurrent or new-onset regurgitation has been reported in up to 23% [43] (level III) of patients following surgery, the majority of studies reported rates ranging from 0% to 11% [107, 109, 110, 143, 193, 196, 200, 201, 214–216, 221] (level I–III).

Response of atypical reflux symptoms to antireflux surgery

Improvement of atypical symptoms has been reported in 67–92% of patients after antireflux surgery [190, 193, 196, 209] (level II–III). Specifically, cough has been shown to significantly improve following laparoscopic antireflux surgery [20, 190, 193, 221, 223, 226] (level II–III) with cure rates of 53% [226] (level II), short-term improvement rates from 69 to 100% [20, 221, 223, 226] (level II), and long-term improvement rates of 71% [223] (level II). Hoarseness [190, 193, 202, 221] (level II–III), sore throat [190, 193] (level II–III), and bronchitis [193, 202] (level III) have also been reported significantly improved following surgery. Improvement has also been reported for pulmonary symptoms [143, 196] (level II–III), aspiration [202, 206] (level III), and wheezing [190, 206] (level II–III) symptoms. While some reports have shown improvement in asthma [20, 193] (level II–III) and laryngitis [193] (level III) following antireflux surgery, others have reported no benefit [143, 202, 221] (level II–III).

Objective outcomes

Functional improvement, including significant increase in LES pressure [32, 33, 38, 47, 122, 146, 198, 199, 215, 221, 223, 224, 226, 228–230] (level I–III) and significant decrease in acid exposure [32–34, 38, 47, 120, 145, 146, 190, 198, 199, 203, 221, 223–225, 228–232] (level I–III) compared with preoperative values are documented in both short- and long-term studies, with pH studies returning to normal in approximately 88–94% of patients [112] (level II).

Postoperative complications

Complication rates following antireflux surgery vary related to experience, technique, and degree and intensity of follow-up. Conversion rates to open surgery for

laparoscopic antireflux surgery range from 0 to 24% [32–34, 39, 41, 43–45, 47, 59, 112, 120–125, 129–132, 145, 146, 157, 188, 195, 196, 198–200, 203, 204, 206, 208, 210, 212, 215, 219–222, 225–227, 229, 230, 232–241] (level I–III); however, most series from high-volume centers report conversion rates <2.4% [32–34, 39] (level I).

Specific intraoperative complications related to laparoscopic antireflux surgery include gastric and esophageal perforation and pneumothorax. The gastric and esophageal perforation rate varies according to technique and experience, with reported ranges from 0 to 4% [33, 34, 38, 44, 45, 47, 112, 120, 123–125, 146, 188, 196, 201, 214, 227, 236, 241, 242] (level I–III) and several authors reporting 0% in series with at least 50 patients [38, 47, 112, 124, 125, 146, 227] (level I–II). The highest incidence of perforation (4%) has been reported after redo fundoplication [241] (level III). Other authors studying techniques of laparoscopic antireflux surgery, specifically the thoracoscopic Belsey, have reported higher gastric and esophageal perforation rates (6.7–9.1%) [237, 243] (level III).

Rates of pneumothorax during laparoscopic antireflux surgery in most series range from 0% to 1.5% [34, 38, 47, 112, 120, 124, 188, 195, 199, 214, 227, 228, 236, 241] (level I–III). Nevertheless, this complication rarely requires intervention, as it is usually involves injury of the pleura but not the lung itself. Two series have evaluated the use of robotic approach and reported rates of 5% in the robot group [130] (level I) and 4% in the laparoscopic group [131] (level I).

The duration of the operation is dependent on the technique used and has been reported to range from 49 to 210 min [43–45, 47, 120–122, 145, 146, 195–198, 200, 201, 203, 206, 208, 215, 219–221, 225, 226, 230, 241] (level I–III). A learning curve has been demonstrated, with improved operating times as the number of cases increases [219, 220] (level II–III) and with high-volume centers reporting shorter operating room times (49–120 min) [33, 34, 38, 107, 110, 119, 124, 125, 130–133, 233] (level I). Length of stay following laparoscopic antireflux surgery ranges between 1 and 4 days [20, 33, 34, 38, 44, 47, 59, 120, 121, 123, 129, 145, 146, 188, 192, 195, 197, 198, 200, 202, 203, 206, 208–210, 214, 215, 220, 221, 225, 241] (level I–III). With regard to the effect of the learning curve on outcome, there is a marked paucity of data, with only one study being identified. The authors compared patient outcomes between the early and late experience of a single surgeon and reported that complication rates did not differ between his first 25 cases and a matched control group of 25 cases approximately 7 years later (level II). Nevertheless, during both periods, patients had high rates of dysphagia (23 vs. 21% at 2 years), persistence of heartburn (27 vs. 25%), and persistence of regurgitation (8 vs. 12%) [56].

Postoperative 30-day mortality has rarely been reported and is usually 0% [33, 34, 188, 190, 196, 204, 209] (level I–III). Complications related to incisions include wound infections, which are reported to range from 0.2 to 3.1% [38, 45, 188, 195, 199] (level II–III), and port-site hernias, ranging from 0.17 to 9% [38, 109, 121, 122, 199, 204] (level I–II). Herniation of the wrap and wrap migration vary related to the technique used and the duration of follow-up and have been reported to range from 0.8 to 26% [32–34, 38, 44, 47, 132, 196, 199, 227, 233] (level I–III). One report demonstrated a significant decrease in the incidence of wrap herniation from 26 to 8% with the use of a mesh buttress at the hiatus [227] (level I). Reoperation rates also vary according to technique, indication, and follow-up and have been reported to range from 0 to 15% [32, 33, 39, 41, 43, 45, 47, 107, 109, 110, 112, 119, 121, 123, 145, 157, 188, 195, 196, 200, 201, 204, 214, 234, 241, 242] (level II–III).

Postoperative use of acid-reducing medications

Resumption of acid-reducing medications in patients after antireflux surgery has been reported to range widely (0–62%) at both short-term [34, 107, 109, 123, 124, 130, 131, 234, 242] and long-term follow-up [31, 41–45, 47, 145, 189–191, 195, 196, 198–202, 204, 207, 209–212, 214, 215, 218, 224, 230, 244] (level I–III). Long-term medication use has been reported to range from 5.8% to 62% [31, 34, 41–44, 47, 107, 109, 196] (level I–III) with most studies reporting rates <20% [41, 43, 44] (level II–III). One randomized controlled trial, however, reported 62% incidence of antacid medication resumption after antireflux surgery [31], which constitutes a very high rate compared with the rest of the literature.

Quality of life and satisfaction with surgery

Satisfaction rates for surgery range from 62 to 97% [20, 41–43, 47, 122, 143, 145, 188, 190, 191, 196, 199, 204, 206–208, 211, 212, 221–223, 230, 241, 244] (level II–III), with long-term satisfaction rates (follow-up >5 years) ranging from 80 to 96% [41, 42, 45, 47, 143, 188, 196, 222] (level II–III). Additionally, 81–95% of patients, in both short- and long-term follow-up, stated that they would undergo surgery again [20, 42, 43, 47, 143, 188, 204, 206, 212, 223] (level II–III). Quality of life significantly improved after laparoscopic antireflux surgery in both early and long-term studies as documented from a variety of quality-of-life surveys, including generic and disease-specific quality-of-life surveys [41–43, 189, 191–193, 197, 209, 213, 214, 224] (level II–III).

Recommendations

1. Laparoscopic antireflux surgery is effective at restoring the mechanical barrier to reflux with significant improvements in LES pressure and acid reflux exposure, can be performed safely with minimal perioperative morbidity and mortality, and leads to high patient satisfaction rates and improved quality of life (grade A).

2. Laparoscopic antireflux surgery is an effective treatment strategy for typical symptoms of GERD with significant improvements in rates of dysphagia, heartburn, and regurgitation and should be considered in appropriately selected patients and be performed by appropriately trained surgeons (grade A).

3. While atypical symptoms improve in a majority of patients after antireflux surgery, symptom persistence is higher compared with patients with typical symptoms and surgeons should therefore carefully select and counsel these patients preoperatively (grade B).

4. Patients undergoing laparoscopic antireflux surgery should be counseled preoperatively about the reported rates of symptom relapse and resumption of acid-reducing medications (grade A).

Barrett's esophagus and antireflux surgery

Definition and demographic

Barrett's esophagus is defined as a metaplastic change in which the squamous epithelium of the esophagus is replaced by a columnar epithelium containing goblet cells [intestinal metaplasia (IM)]. This metaplastic process is believed to be initiated by inflammation and injury induced by chronically refluxed acid and bile [245–248]. Barrett's esophagus is present in 1.65% of the general population, 8.6% of symptomatic GERD patients presenting to a tertiary care center, and 10.8% of patients undergoing antireflux surgery [249–251]. Barrett's esophagus (neoplasia not present) is associated with a significantly increased risk for developing esophageal adenocarcinoma (approximately 100-fold) over that of the general population [252, 253]. As intraepithelial neoplasia develops, the annual per-patient risk for cancer increases further [245, 247, 248, 254–256].

Preoperative endoscopy

Upper endoscopy should be performed as part of the preoperative workup for antireflux surgery, as erosive esophagitis and Barrett's esophagus are independent objective diagnostic criteria for GERD. Diagnosis of Barrett's esophagus, depending on histological grade, may alter patient eligibility for and timing of antireflux surgery. When a columnar-lined esophagus is detected for the first time at preoperative endoscopy, four-quadrant biopsies are obtained from every 1–2 cm of the affected portion of the esophagus to confirm Barrett's and determine its histological grade [245, 247, 257]. Endoscopic mucosal resection (EMR) may be used to remove eligible areas of nodularity or ulceration to rule out advanced neoplasia warranting immediate intervention (level II). If a patient has been diagnosed with Barrett's before preoperative endoscopy, expert review of the prior pathology or repeat biopsy may be considered to confirm the histological grade before antireflux surgery (level III).

Histological assessment of Barrett's

Biopsy specimens from a Barrett's esophagus are graded according to the presence or absence of neoplasia: (1) no neoplasia (also known as nonneoplastic IM), (2) indefinite for neoplasia (IND), (3) low-grade intraepithelial neoplasia (LGIN), (4) high-grade intraepithelial neoplasia (HGIN), and (5) intramucosal carcinoma (IMC). Standard, endoscopically acquired biopsy specimens may not penetrate deeply enough into the esophageal wall to rule out involvement of the submucosa by cancer, therefore EMR or endoscopic ultrasound (EUS) may be indicated in cases suspicious for advanced neoplasia (level II). A finding of neoplasia prompts review by more than one expert pathologist to confirm the diagnosis and grade, given the interobserver variability reported for Barrett's neoplasia [248, 257–260] (level I).

Impact of histology findings on antireflux surgery candidacy and timing of surgery

A finding of HGIN or adenocarcinoma on preoperative biopsy requires immediate attention and may delay (in the case of HGIN and IMC) or exclude (in the case of adenocarcinoma with submucosal invasion or deeper) antireflux surgery. Additional workup for HGIN or adenocarcinoma may include chest computed tomography (CT), EUS, and/or staging EMR (if visible lesion exists that is amenable to resection) [247, 257, 261–265] (level II).

Adenocarcinoma involving the submucosa (or deeper) is managed with esophagectomy, radiation therapy, and/or chemotherapy, as indicated by tumor stage.

HGIN and IMC have been historically managed with esophagectomy, although more recently certain endoscopic techniques [photodynamic therapy (PDT), EMR, and radiofrequency ablation (RFA)], alone and in combination, have been shown in randomized trials (as well as cohort trials and case series) to be safe and effective for complete histological eradication of the targeted lesion and for reducing the risk of neoplastic progression [264–285] (level I). Endoscopic techniques have become first-line therapy for HGIN and IMC at most centers (level III). If endoscopic therapy is elected, antireflux surgery may be delayed until complete eradication of the Barrett's segment and accompanying neoplasia is achieved (level III).

Nonneoplastic IM, IND or LGIN may be effectively treated with endoscopic eradication followed by long-term

surveillance endoscopy (level I and II) or surveillance endoscopy alone (level III). If surveillance alone is elected, antireflux surgery may be performed immediately. If endoscopic eradication is elected, antireflux surgery may be performed before, during or after ablative therapy (level III). Of the ablation modalities available, RFA has been shown to achieve high rates of complete histological eradication of IM, IND, and LGIN with an acceptable adverse event profile [277–285] (level I). Furthermore, cost–utility studies show that ablative therapy is the preferred strategy over surveillance alone (all grades) and esophagectomy (HGIN) [286–289].

Antireflux surgery for Barrett's esophagus

The goals of treatment for patients with Barrett's esophagus are similar to those of patients with gastroesophageal reflux disease and include relief of symptoms and cessation of ongoing epithelial damage related to reflux.

Despite numerous publications on the role of antireflux surgery in Barrett's esophagus, there are few randomized controlled trials. In a recent review evaluating the randomized trials in the treatment of Barrett's done by Faybush and Sampliner in 2005 [290], only one randomized trial compared medical and surgical therapy. This study, by Parilla et al. [291], compared the results of histamine 2 receptor antagonist (H2RA) and proton pump inhibitors (PPIs) versus open Nissen fundoplication, with the outcome measure being preventing progression of Barrett's esophagus to dysplasia and adenocarcinoma. With median follow-up of 5 years, they reported that the Barrett's esophagus segment did not change during the treatment period, with high-grade dysplasia developing in two patients in each arm and no significant differences between the two groups in terms of progression to dysplasia or malignancy [291]. They concluded that surgery cannot be advocated as the treatment of choice in patients with Barrett's esophagus and that PPI alone does not eliminate the risk of dysplasia or adenocarcinoma [291] (level I).

Since 2005, there have been other published studies evaluating surgical and medical treatment for Barrett's esophagus. A nonrandomized prospective study by Rossi et al. compared high-dose PPIs versus laparoscopic Nissen fundoplication in patients with low-grade dysplasia and reported significantly improved regression of Barrett's esophagus in the surgical group [25] (level II).

Recently, a randomized prospective trial comparing treatment outcomes in patients with and without Barrett's esophagus submitted to laparoscopic antireflux surgery or PPI therapy reported that clinical response to therapy at 3 years was similar in the Barrett's esophagus compared with the non-Barrett's-esophagus group [251]. They also reported similar symptom outcomes [Gastrointestinal

Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD)] in the medical versus surgical treatment arms but reported improved control of reflux using pH data [251] (level I).

Surveillance of Barrett's esophagus after antireflux surgery

Medical professional society guidelines recommend surveillance endoscopy with four-quadrant biopsies to detect neoplastic progression every 3 years for nonneoplastic IM, every 6–12 months for LGIN, and every 3 months for HGIN [257]. In patients who have had successful complete eradication of Barrett's esophagus, surveillance should continue according to their baseline Barrett's histology grade until further evidence is available. Antireflux surgery does not change these recommended surveillance guidelines. Furthermore, there is no evidence indicating that surveillance is more difficult or less effective after antireflux surgery [210, 216, 247, 292, 293].

Recommendations

1. Detection of Barrett's esophagus with adenocarcinoma involving the submucosa or deeper excludes the patient from antireflux surgery and demands comprehensive stage-specific therapy (esophagectomy, chemotherapy, and/or radiation therapy) (grade A).

2. HGIN and IMC can be effectively treated with endoscopic therapy including PDT, EMR, and RFA, alone or in combination (grade B). Antireflux surgery can be performed after achieving complete histological eradication of the lesion with endoscopic therapy (grade C). Esophagectomy remains an option for HGIN and IMC, either as salvage in the case of endoscopic therapy failure or as primary therapy.

3. Antireflux surgery may be performed in a patient with nonneoplastic IM, IND, and LGIN, with or without endoscopic therapy to eradicate the Barrett's tissue. Specifically, RFA has been shown to be safe, clinically effective, and cost-effective in these disease states and may be performed in eligible patients before, during, or after antireflux surgery (grade B).

4. Antireflux surgery does not alter the need for continued surveillance endoscopy in patients with Barrett's esophagus. Patients who have undergone endoscopic ablative therapy and antireflux surgery should continue surveillance endoscopy according to their baseline grade of Barrett's (grade A).

5. The available evidence is inconclusive about the resolution or improvement of Barrett's after antireflux surgery.

---

no conflicts of interest or financial ties to disclosure. Dimitrios Stefanidis have received honoraria from CR Bard, Inc and WL Gore and Associates for speaking/ teaching.

Appendix 1: Medline Search Strategy

Database: Ovid MEDLINE(R) (1950 to March Week 2 2008) Search Strategy:

1. Gastroesophageal Reflux/ (16387)
2. exp Surgical Procedures, Minimally invasive/ (190792)
3. Robotics/ (5031)
4. Fundoplication/ (2421)
5. (*Gastroesophageal Reflux/ or *Fundoplication/) and (2 or 3) (3359)
6. limit 5 to (comment or letter or news or newspaper article) (185)
7. 5 not 6 (3174)
8. limit 7 to english language (2522)
9. 8 and *Gastroesophageal Reflux/th, su (1104)
10. limit 9 to systematic reviews (46)
11. limit 9 to meta analysis (3)
12. limit 9 to randomized controlled trial (66)
13. limit 9 to evidence based medicine reviews (3)
14. 10 or 11 or 12 or 13 (112)
15. 9 not 14 (992)
16. 16 limit 15 to (clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or consensus development conference or consensus development conference, nih or controlled clinical trial or guideline or practice guideline) (59)
17. 17 15 not 16 (933)
18. 18 limit 17 to "review articles" (236)
19. 19 17 not 18 (699)
20. 20 (surg$ or endoscop$ or laparo$ or digest$ or gastro$ or gut).jw. (748495)
21. 21 19 and 20 (604)
22. 22 limit 21 to humans (586)
23. 23 limit 22 to yr="2003–2008" (236)

Appendix 2

This document was prepared and revised by the SAGES Guidelines Committee:

Dimitrios Stefanidis, MD, PhD
WilliamW. Hope, MD
Geoffrey P. Kohn, MD
Patrick R. Reardon, MD
E. Matt Ritter, MD
Keith Gersin, MD

Thom E. Lobe, MD
Keith Apelgren, MD
Ziad Awad, MD
L. Michael Brunt, MD
Ronald Clements, MD
David Earle, MD
David Edelman, MD
Timothy Farrell, MD
Erika Fellinger, MD
Stephen Haggerty, MD
Jeffrey Hazey, MD
Steven Heneghan, MD
Gregory Kahn, MD
James Korndorffer, MD
Henry Lujan, MD
Lisa Martin Hawver, MD
Sumeet Mittal, MD
Jonathan Myers, MD
David Overby, MD
Jonathan Pearl, MD
Raymond Price, MD
William Reed, MD
David Renton, MD
John Roth, MD
Alan Saber, MD
Julio Teixeria, MD
Andrew Wright, MD
Marc Zerey, MD
William Richardson, MD, Co-Chair
Robert Fanelli, MD, Chair

It was reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), February 2010.

Requests for prints should be sent to:
Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)
11300 West Olympic Blvd., Suite 600
Los Angeles, CA 90064
Phone: (310) 437-0544
Fax: (310) 437 0585
E-mail: publications@sages.org
http://www.sages.org/
This is a revision of a SAGES publication, which was printed June 2001.

References

1. Varin O, Velstra B, De Sutter S, Ceelen W (2009) Total vs partial fundoplication in the treatment of gastroesophageal reflux disease: a meta-analysis. Arch Surg 144:273–278
2. Granderath FA, Kamolz T, Schweiger UM, Pointner R (2003) Laparoscopic refundoplication with prosthetic hiatal closure for

recurrent hiatal hernia after primary failed antireflux surgery. Arch Surg 138:902–907

3. Everhart JE (ed) (2008) The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Government Printing Office, Washington, DC. NIH Publication No. 09-6443

4. Falk GW, Fennerty MB, Rothstein RI (2006) AGA Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 131:1313–1314

5. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV (2008) American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 135:1383-1391 (1391: e1381–1385)

6. Wetscher GJ, Redmont EJ, Vititi LMH (1993) Pathophysiology of gastroesophageal reflux disease. In: Hinder RA (ed) Gastroesophageal reflux disease. R.G. Landes, Austin, TX, pp 7–29

7. Little AG (1992) Mechanisms of action of antireflux surgery: theory and fact. World J Surg 16:320–325

8. Ireland AC, Holloway RH, Toouli J, Dent J (1993) Mechanisms underlying the antireflux action of fundoplication. Gut 34: 303–308

9. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L (1999) Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45:172–180

10. Tam WC, Holloway RH, Dent J, Rigda R, Schoeman MN (2004) Impact of endoscopic suturing of the gastroesophageal junction on lower esophageal sphincter function and gastroesophageal reflux in patients with reflux disease. Am J Gastroenterol 99:195–202

11. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L (1996) The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 111:85–92

12. Hassall E (1993) Barrett's esophagus: congenital or acquired? Am J Gastroenterol 88:819–824

13. Francalanci P, De Angelis P, Minnei F, Diomedi Camassei F, Torroni F, Dall'Oglio L, Callea F (2008) Eosinophilic esophagitis and Barrett's esophagus: an occasional association or an overlap disease? Esophageal 'double trouble' in two children. Digestion 77:16–19

14. Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W, Hinder RA, Albertucci M (1992) Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 87: 1102–1111

15. Gunnarsdottir A, Stenstrom P, Arnbjornsson E (2007) 48-Hour wireless oesophageal pH-monitoring in children: are two days better than one? Eur J Pediatr Surg 17:378–381

16. Ayazi S, Lipham JC, Portale G, Peyre CG, Streets CG, Leers JM, Demeester SR, Banki F, Chan LS, Hagen JA, Demeester TR (2009) Bravo catheter-free pH monitoring: normal values, concordance, optimal diagnostic thresholds, and accuracy. Clin Gastroenterol Hepatol 7:60–67

17. Castell DO, Vela M (2001) Combined multichannel intraluminal impedance and pH-metry: an evolving technique to measure type and proximal extent of gastroesophageal reflux. Am J Med 111(Suppl 8A):157S–159S

18. Spechler SJ, Goyal RK (1996) The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 110:614–621

19. Lagergren J, Bergstrom R, Lindgren A, Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831

20. Rakita S, Villadolid D, Thomas A, Bloomston M, Albrink M, Goldin S, Rosemurgy A (2006) Laparoscopic Nissen fundoplication offers high patient satisfaction with relief of extraesophageal symptoms of gastroesophageal reflux disease. Am Surg 72:207–212

21. Meyer TK, Olsen E, Merati A (2004) Contemporary diagnostic and management techniques for extraesophageal reflux disease. Curr Opin Otolaryngol Head Neck Surg 12:519–524

22. Lindstrom DR, Wallace J, Loehrl TA, Merati AL, Toohill RJ (2002) Nissen fundoplication surgery for extraesophageal manifestations of gastroesophageal reflux (EER). Laryngoscope 112:1762–1765

23. Oelschlager BK, Eubanks TR, Oleynikov D, Pope C, Pellegrini CA (2002) Symptomatic and physiologic outcomes after operative treatment for extraesophageal reflux. Surg Endosc 16: 1032–1036

24. Yau P, Watson DI, Devitt PG, Game PA, Jamieson GG (2000) Laparoscopic antireflux surgery in the treatment of gastroesophageal reflux in patients with Barrett esophagus. Arch Surg 135:801–805

25. Rossi M, Barreca M, de Bortoli N, Renzi C, Santi S, Gennai A, Bellini M, Costa F, Conio M, Marchi S (2006) Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann Surg 243:58–63

26. Chang EY, Morris CD, Seltman AK, O'Rourke RW, Chan BK, Hunter JG, Jobe BA (2007) The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg 246:11–21

27. Fibbe C, Layer P, Keller J, Strate U, Emmermann A, Zornig C (2001) Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study. Gastroenterology 121:5–14

28. Yang H, Watson DI, Kelly J, Lally CJ, Myers JC, Jamieson GG (2007) Esophageal manometry and clinical outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 11:1126–1133

29. Frantzides CT, Carlson MA, Madan AK, Stewart ET, Smith C (2003) Selective use of esophageal manometry and 24-hour pH monitoring before laparoscopic fundoplication. J Am Coll Surg 197:358–363 (discussion 363–354)

30. Wayman J, Myers JC, Jamieson GG (2007) Preoperative gastric emptying and patterns of reflux as predictors of outcome after laparoscopic fundoplication. Br J Surg 94:592–598

31. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W (2001) Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285:2331–2338

32. Anvari M, Allen C, Marshall J, Armstrong D, Goeree R, Ungar W, Goldsmith C (2006) A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up. Surg Innov 13:238–249

33. Mahon D, Rhodes M, Decadt B, Hindmarsh A, Lowndes R, Beckingham I, Koo B, Newcombe RG (2005) Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux. Br J Surg 92:695–699

34. Mehta S, Bennett J, Mahon D, Rhodes M (2006) Prospective trial of laparoscopic Nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: seven-year follow-up. J Gastrointest Surg 10:1312–1316 (discussion 1316–1317)

35. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Lamm M, Blomqvist A, Hatlebakk JG, Janatuinen E, Levander

K, Nystrom P, Wiklund I (2000) Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 12:879–887

36. Lundell L, Attwood S, Ell C, Fiocca R, Galmiche JP, Hatlebakk J, Lind T, Junghard O (2008) Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 57:1207–1213

37. Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Malm A, Sutherland I, Walan A (2007) Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. Br J Surg 94: 198–203

38. Anvari M, Allen C, Borm A (1995) Laparoscopic Nissen fundoplication is a satisfactory alternative to long-term omeprazole therapy. Br J Surg 82:938–942

39. Ciovica R, Gadenstatter M, Klingler A, Lechner W, Riedl O, Schwab GP (2006) Quality of life in GERD patients: medical treatment versus antireflux surgery. J Gastrointest Surg 10: 934–939

40. Jenkinson AD, Kadirkamanathan SS, Scott SM, Yazaki E, Evans DF (2004) Relationship between symptom response and oesophageal acid exposure after medical and surgical treatment for gastro-oesophageal reflux disease. Br J Surg 91:1460–1465

41. Dassinger MS, Torquati A, Houston HL, Holzman MD, Sharp KW, Richards WO (2004) Laparoscopic fundoplication: 5-year follow-up. Am Surg 70:691–694 (discussion 694–695)

42. Kamolz T, Granderath FA, Schweiger UM, Pointner R (2005) Laparoscopic Nissen fundoplication in patients with nonerosive reflux disease. Long-term quality-of-life assessment and surgical outcome. Surg Endosc 19:494–500

43. Rosenthal R, Peterli R, Guenin MO, von Flue M, Ackermann C (2006) Laparoscopic antireflux surgery: long-term outcomes and quality of life. J Laparoendosc Adv Surg Tech A 16:557–561

44. Zaninotto G, Portale G, Costantini M, Rizzetto C, Guirroli E, Ceolin M, Salvador R, Rampado S, Prandin O, Ruol A, Ancona E (2007) Long-term results (6–10 years) of laparoscopic fundoplication. J Gastrointest Surg 11:1138–1145

45. Pessaux P, Arnaud JP, Delattre JF, Meyer C, Baulieux J, Mosnier H (2005) Laparoscopic antireflux surgery: five-year results and beyond in 1340 patients. Arch Surg 140:946–951

46. Lord RV, Kaminski A, Oberg S, Bowrey DJ, Hagen JA, DeMeester SR, Sillin LF, Peters JH, Crookes PF, DeMeester TR (2002) Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication. J Gastrointest Surg 6:3–9 (discussion 10)

47. Anvari M, Allen C (2003) Five-year comprehensive outcomes evaluation in 181 patients after laparoscopic Nissen fundoplication. J Am Coll Surg 196:51–57 (discussion 57–58; author reply 58–59)

48. Myrvold HE, Lundell L, Miettinen P, Pedersen SA, Liedman B, Hatlebakk J, Julkunen R, Levander K, Lamm M, Mattson C, Carlsson J, Stahlhammar NO (2001) The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut 49: 488–494

49. Heudebert GR, Marks R, Wilcox CM, Centor RM (1997) Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 112: 1078–1086

50. Arguedas MR, Heudebert GR, Klapow JC, Centor RM, Eloubeidi MA, Wilcox CM, Spechler SJ (2004) Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection. Am J Gastroenterol 99:1023–1028

51. Attwood SE, Lundell L, Ell C, Galmiche JP, Hatlebakk J, Fiocca R, Lind T, Eklund S, Junghard O (2008) Standardization of surgical technique in antireflux surgery: the LOTUS Trial experience. World J Surg 32:995–998

52. Soper NJ, Dunnegan D (1999) Anatomic fundoplication failure after laparoscopic antireflux surgery. Ann Surg 229:669–676 (discussion 676–667)

53. Watson DI, Baigrie RJ, Jamieson GG (1996) A learning curve for laparoscopic fundoplication. Definable, avoidable, or a waste of time? Ann Surg 224:198–203

54. Deschamps C, Allen MS, Trastek VF, Johnson JO, Pairolero PC (1998) Early experience and learning curve associated with laparoscopic Nissen fundoplication. J Thorac Cardiovasc Surg 115:281–284 (discussion 284–285)

55. Contini S, Bertele A, Nervi G, Zinicola R, Scarpignato C (2002) Quality of life for patients with gastroesophageal reflux disease 2 years after laparoscopic fundoplication. Evaluation of the results obtained during the initial experience. Surg Endosc 16:1555–1560

56. Contini S, Scarpignato C (2004) Does the learning phase influence the late outcome of patients with gastroesophageal reflux disease after laparoscopic fundoplication? Surg Endosc 18:266–271

57. Funch-Jensen P, Bendixen A, Iversen MG, Kehlet H (2008) Complications and frequency of redo antireflux surgery in Denmark: a nationwide study, 1997–2005. Surg Endosc 22: 627–630

58. Bais JE, Bartelsman JF, Bonjer HJ, Cuesta MA, Go PM, Klinkenberg-Knol EC, van Lanschot JJ, Nadorp JH, Smout AJ, van der Graaf Y, Gooszen HG (2000) Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet 355:170–174

59. Catarci M, Gentileschi P, Papi C, Carrara A, Marrese R, Gaspari AL, Grassi GB (2004) Evidence-based appraisal of antireflux fundoplication. Ann Surg 239:325–337

60. Chrysos E, Tsiaoussis J, Athanasakis E, Zoras O, Vassilakis JS, Xynos E (2002) Laparoscopic vs open approach for Nissen fundoplication. A comparative study. Surg Endosc 16: 1679–1684

61. Draaisma WA, Buskens E, Bais JE, Simmermacher RK, Rijnhart-de Jong HG, Broeders IA, Gooszen HG (2006) Randomized clinical trial and follow-up study of cost-effectiveness of laparoscopic versus conventional Nissen fundoplication. Br J Surg 93:690–697

62. Draaisma WA, Rijnhart-de Jong HG, Broeders IA, Smout AJ, Furnee EJ, Gooszen HG (2006) Five-year subjective and objective results of laparoscopic and conventional Nissen fundoplication: a randomized trial. Ann Surg 244:34–41

63. Franzen T, Anderberg B, Wiren M, Johansson KE (2005) Long-term outcome is worse after laparoscopic than after conventional Nissen fundoplication. Scand J Gastroenterol 40:1261–1268

64. Hakanson BS, Thor KB, Thorell A, Ljungqvist O (2007) Open vs laparoscopic partial posterior fundoplication. A prospective randomized trial. Surg Endosc 21:289–298

65. Heikkinen TJ, Haukipuro K, Bringman S, Ramel S, Sorasto A, Hulkko A (2000) Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. A prospective randomized trial. Surg Endosc 14:1019–1023

66. Heikkinen TJ, Haukipuro K, Koivukangas P, Sorasto A, Autio R, Sodervik H, Makela H, Hulkko A (1999) Comparison of costs between laparoscopic and open Nissen fundoplication: a prospective randomized study with a 3-month followup. J Am Coll Surg 188:368–376

67. Heikkinen TJ, Haukipuro K, Sorasto A, Autio R, Sodervik H, Makela H, Hulkko A (2000) Short-term symptomatic outcome

and quality of life after laparoscopic versus open Nissen fundoplication: a prospective randomized trial. Int J Surg Investig 2:33–39

68. Laine S, Rantala A, Gullichsen R, Ovaska J (1997) Laparoscopic vs conventional Nissen fundoplication. A prospective randomized study. Surg Endosc 11:441–444

69. Luostarinen M, Virtanen J, Koskinen M, Matikainen M, Isolauri J (2001) Dysphagia and oesophageal clearance after laparoscopic versus open Nissen fundoplication. A randomized, prospective trial. Scand J Gastroenterol 36:565–571

70. McHoney M, Eaton S, Wade A, Klein NJ, Stefanutti G, Booth C, Kiely EM, Curry JI, Drake DP, Pierro A (2005) Inflammatory response in children after laparoscopic vs open Nissen fundoplication: randomized controlled trial. J Pediatr Surg 40: 908–913 (discussion 913–904)

71. Nilsson G, Larsson S, Johnsson F (2000) Randomized clinical trial of laparoscopic versus open fundoplication: blind evaluation of recovery and discharge period. Br J Surg 87:873–878

72. Nilsson G, Larsson S, Johnsson F (2002) Randomized clinical trial of laparoscopic versus open fundoplication: evaluation of psychological well-being and changes in everyday life from a patient perspective. Scand J Gastroenterol 37:385–391

73. Nilsson G, Wenner J, Larsson S, Johnsson F (2004) Randomized clinical trial of laparoscopic versus open fundoplication for gastro-oesophageal reflux. Br J Surg 91:552–559

74. Perttila J, Salo M, Ovaska J, Gronroos J, Lavonius M, Katila A, Lahteenmaki M, Pulkki K (1999) Immune response after laparoscopic and conventional Nissen fundoplication. Eur J Surg 165:21–28

75. Peters MJ, Mukhtar A, Yunus RM, Khan S, Pappalardo J, Memon B, Memon MA (2009) Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery. Am J Gastroenterol 104:1548–1561 (quiz 1547, 1562)

76. Salminen PT, Hiekkanen HI, Rantala AP, Ovaska JT (2007) Comparison of long-term outcome of laparoscopic and conventional Nissen fundoplication: a prospective randomized study with an 11-year follow-up. Ann Surg 246:201–206

77. Wenner J, Nilsson G, Oberg S, Melin T, Larsson S, Johnsson F (2001) Short-term outcome after laparoscopic and open 360 degrees fundoplication. A prospective randomized trial. Surg Endosc 15:1124–1128

78. Ackroyd R, Watson DI, Majeed AW, Troy G, Treacy PJ, Stoddard CJ (2004) Randomized clinical trial of laparoscopic versus open fundoplication for gastro-oesophageal reflux disease. Br J Surg 91:975–982

79. Sietses C, Wiezer MJ, Eijsbouts QA, Beelen RH, van Leeuwen PA, von Blomberg BM, Meijer S, Cuesta MA (1999) A prospective randomized study of the systemic immune response after laparoscopic and conventional Nissen fundoplication. Surgery 126:5–9

80. Sietses C, Wiezer MJ, Eijsbouts QA, van Leeuwen PA, Beelen RH, Meijer S, Cuesta MA (2000) The influence of laparoscopic surgery on postoperative polymorphonuclear leukocyte function. Surg Endosc 14:812–816

81. Baigrie RJ, Cullis SN, Ndhluni AJ, Cariem A (2005) Randomized double-blind trial of laparoscopic Nissen fundoplication versus anterior partial fundoplication. Br J Surg 92:819–823

82. Chrysos E, Tsiaoussis J, Zoras OJ, Athanasakis E, Mantides A, Katsamouris A, Xynos E (2003) Laparoscopic surgery for gastroesophageal reflux disease patients with impaired esophageal peristalsis: total or partial fundoplication? J Am Coll Surg 197:8–15

83. Hagedorn C, Lonroth H, Rydberg L, Ruth M, Lundell L (2002) Long-term efficacy of total (Nissen-Rossetti) and posterior partial (Toupet) fundoplication: results of a randomized clinical trial. J Gastrointest Surg 6:540–545

84. Laws HL, Clements RH, Swillie CM (1997) A randomized, prospective comparison of the Nissen fundoplication versus the Toupet fundoplication for gastroesophageal reflux disease. Ann Surg 225:647–653 (discussion 654)

85. Lundell L, Abrahamsson H, Ruth M, Sandberg N, Olbe LC (1991) Lower esophageal sphincter characteristics and esophageal acid exposure following partial or 360 degrees fundoplication: results of a prospective, randomized, clinical study. World J Surg 15:115–120 (discussion 121)

86. Segol P, Hay JM, Pottier D (1989) Surgical treatment of gastroesophageal reflux: which operation to choose: Nissen, Toupet or Lortat-Jacob? A multicenter randomized trial. Gastroenterol Clin Biol 13:873–879

87. Walker SJ, Holt S, Sanderson CJ, Stoddard CJ (1992) Comparison of Nissen total and Lind partial transabdominal fundoplication in the treatment of gastro-oesophageal reflux. Br J Surg 79:410–414

88. Watson DI, Jamieson GG, Lally C, Archer S, Bessell JR, Booth M, Cade R, Cullingford G, Devitt PG, Fletcher DR, Hurley J, Kiroff G, Martin CJ, Martin IJ, Nathanson LK, Windsor JA (2004) Multicenter, prospective, double-blind, randomized trial of laparoscopic Nissen vs anterior 90 degrees partial fundoplication. Arch Surg 139:1160–1167

89. Watson DI, Jamieson GG, Pike GK, Davies N, Richardson M, Devitt PG (1999) Prospective randomized double-blind trial between laparoscopic Nissen fundoplication and anterior partial fundoplication. Br J Surg 86:123–130

90. Spence GM, Watson DI, Jamiesion GG, Lally CJ, Devitt PG (2006) Single center prospective randomized trial of laparoscopic Nissen versus anterior 90 degrees fundoplication. J Gastrointest Surg 10:698–705

91. Thor KB, Silander T (1989) A long-term randomized prospective trial of the Nissen procedure versus a modified Toupet technique. Ann Surg 210:719–724

92. Zornig C, Strate U, Fibbe C, Emmermann A, Layer P (2002) Nissen vs Toupet laparoscopic fundoplication. Surg Endosc 16:758–766

93. Lundell L, Abrahamsson H, Ruth M, Rydberg L, Lonroth H, Olbe L (1996) Long-term results of a prospective randomized comparison of total fundic wrap (Nissen–Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux. Br J Surg 83:830–835

94. Strate U, Emmermann A, Fibbe C, Layer P, Zornig C (2008) Laparoscopic fundoplication: Nissen versus Toupet two-year outcome of a prospective randomized study of 200 patients regarding preoperative esophageal motility. Surg Endosc 22:21–30

95. Hunter JG, Trus TL, Branum GD, Waring JP, Wood WC (1996) A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. Ann Surg 223:673–685 (discussion 685–677)

96. Patti MG, Arcerito M, Feo CV, De Pinto M, Tong J, Gantert W, Tyrrell D, Way LW (1998) An analysis of operations for gastroesophageal reflux disease: identifying the important technical elements. Arch Surg 133:600–606 (discussion 606–607)

97. Booth MI, Stratford J, Jones L, Dehn TC (2008) Randomized clinical trial of laparoscopic total (Nissen) versus posterior partial (Toupet) fundoplication for gastro-oesophageal reflux disease based on preoperative oesophageal manometry. Br J Surg 95:57–63

98. Cai W, Watson DI, Lally CJ, Devitt PG, Game PA, Jamieson GG (2008) Ten-year clinical outcome of a prospective randomized clinical trial of laparoscopic Nissen versus anterior 180(degrees) partial fundoplication. Br J Surg 95:1501–1505

99. Woodcock SA, Watson DI, Lally C, Archer S, Bessell JR, Booth M, Cade R, Cullingford GL, Devitt PG, Fletcher DR, Hurley J,

Jamieson GG, Kiroff G, Martin CJ, Martin IJ, Nathanson LK, Windsor JA (2006) Quality of life following laparoscopic anterior 90 degrees versus Nissen fundoplication: results from a multicenter randomized trial. World J Surg 30:1856–1863

100. Ludemann R, Watson DI, Jamieson GG, Game PA, Devitt PG (2005) Five-year follow-up of a randomized clinical trial of laparoscopic total versus anterior 180 degrees fundoplication. Br J Surg 92:240–243

101. Engstrom C, Lonroth H, Mardani J, Lundell L (2007) An anterior or posterior approach to partial fundoplication? Long-term results of a randomized trial. World J Surg 31:1221–1225 (discussion 1226–1227)

102. Mickevicius A, Endzinas Z, Kiudelis M, Jonaitis L, Kupcinskas L, Maleckas A, Pundzius J (2008) Influence of wrap length on the effectiveness of Nissen and Toupet fundoplication: a prospective randomized study. Surg Endosc 22:2269–2276

103. Guerin E, Betroune K, Closset J, Mehdi A, Lefebvre JC, Houben JJ, Gelin M, Vaneukem P, El Nakadi I (2007) Nissen versus Toupet fundoplication: results of a randomized and multicenter trial. Surg Endosc 21:1985–1990

104. Jobe BA, Wallace J, Hansen PD, Swanstrom LL (1997) Evaluation of laparoscopic Toupet fundoplication as a primary repair for all patients with medically resistant gastroesophageal reflux. Surg Endosc 11:1080–1083

105. Patti MG, Robinson T, Galvani C, Gorodner MV, Fisichella PM, Way LW (2004) Total fundoplication is superior to partial fundoplication even when esophageal peristalsis is weak. J Am Coll Surg 198:863–869 (discussion 869–870)

106. Hagedorn C, Jonson C, Lonroth H, Ruth M, Thune A, Lundell L (2003) Efficacy of an anterior as compared with a posterior laparoscopic partial fundoplication: results of a randomized, controlled clinical trial. Ann Surg 238:189–196

107. Yang H, Watson DI, Lally CJ, Devitt PG, Game PA, Jamieson GG (2008) Randomized trial of division versus nondivision of the short gastric vessels during laparoscopic Nissen fundoplication: 10-year outcomes. Ann Surg 247:38–42

108. Engstrom C, Blomqvist A, Dalenback J, Lonroth H, Ruth M, Lundell L (2004) Mechanical consequences of short gastric vessel division at the time of laparoscopic total fundoplication. J Gastrointest Surg 8:442–447

109. O'Boyle CJ, Watson DI, Jamieson GG, Myers JC, Game PA, Devitt PG (2002) Division of short gastric vessels at laparoscopic Nissen fundoplication: a prospective double-blind randomized trial with 5-year follow-up. Ann Surg 235:165–170

110. Blomqvist A, Dalenback J, Hagedorn C, Lonroth H, Hyltander A, Lundell L (2000) Impact of complete gastric fundus mobilization on outcome after laparoscopic total fundoplication. J Gastrointest Surg 4:493–500

111. Chrysos E, Tzortzinis A, Tsiaoussis J, Athanasakis H, Vasssilakis J, Xynos E (2001) Prospective randomized trial comparing Nissen to Nissen-Rossetti technique for laparoscopic fundoplication. Am J Surg 182:215–221

112. Gad El-Hak N, Abo Zied M, Aboelenen A, Fouad A, Abd Alla T, El-Shoubary M, Kandel T, Hamdy E, Abdel Wahab M, Fathy O, El-ebidy G, Sultan A, Elfiky A, Elghwalby N, Ezzat F (2005) Short gastric vessels division in Laparoscopic Nissen Fundoplication. Hepatogastroenterology 52:1742–1747

113. Neufeld M, Graham A (2007) Levels of evidence available for techniques in antireflux surgery. Dis Esophagus 20:161–167

114. Donahue PE, Larson GM, Stewardson RH, Bombeck CT (1977) Floppy Nissen fundoplication. Rev Surg 34:223–224

115. DeMeester TR, Bonavina L, Albertucci M (1986) Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients. Ann Surg 204:9–20

116. Wu JS, Dunnegan DL, Luttmann DR, Soper NJ (1996) The influence of surgical technique on clinical outcome of laparoscopic Nissen fundoplication. Surg Endosc 10:1164–1169 (discussion 1169–1170)

117. Watson DI, Pike GK, Baigrie RJ, Mathew G, Devitt PG, Britten-Jones R, Jamieson GG (1997) Prospective double-blind randomized trial of laparoscopic Nissen fundoplication with division and without division of short gastric vessels. Ann Surg 226:642–652

118. Anvari M, Allen C (1998) Laparoscopic Nissen fundoplication: two-year comprehensive follow-up of a technique of minimal paraesophageal dissection. Ann Surg 227:25–32

119. Watson DI, Jamieson GG, Devitt PG, Kennedy JA, Ellis T, Ackroyd R, Lafullarde T, Game PA (2001) A prospective randomized trial of laparoscopic Nissen fundoplication with anterior vs posterior hiatal repair. Arch Surg 136:745–751

120. Gotley DC, Smithers BM, Rhodes M, Menzies B, Branicki FJ, Nathanson L (1996) Laparoscopic Nissen fundoplication–200 consecutive cases. Gut 38:487–491

121. Lefebvre JC, Belva P, Takieddine M, Vaneukem P (1998) Laparoscopic Toupet fundoplication: prospective study of 100 cases. Results at one year and literature review. Acta Chir Belg 98:1–4

122. Zaninotto G, Molena D, Ancona E (2000) A prospective multicenter study on laparoscopic treatment of gastroesophageal reflux disease in Italy: type of surgery, conversions, complications, and early results. Study Group for the laparoscopic treatment of gastroesophageal reflux disease of the Italian society of endoscopic surgery (SICE). Surg Endosc 14:282–288

123. Victorzon M, Tolonen P (2003) Symptomatic outcome of laparoscopic fundoplication, using a minimal dissection technique. Scand J Surg 92:138–143

124. Kala Z, Dolina J, Kysela P, Hermanova M, Prochazka V, Kroupa R, Izakovicova-Holla L, Hep A (2006) Intraoperative manometry of the lower esophageal sphincter pressure during laparoscopic antireflux surgery with a mechanical calibration–early results. Hepatogastroenterology 53:710–714

125. Morino M, Pellegrino L, Giaccone C, Garrone C, Rebecchi F (2006) Randomized clinical trial of robot-assisted versus laparoscopic Nissen fundoplication. Br J Surg 93:553–558

126. Granderath FA, Schweiger UM, Kamolz T, Asche KU, Pointner R (2005) Laparoscopic Nissen fundoplication with prosthetic hiatal closure reduces postoperative intrathoracic wrap herniation: preliminary results of a prospective randomized functional and clinical study. Arch Surg 140:40–48

127. Granderath FA (2007) Measurement of the esophageal hiatus by calculation of the hiatal surface area (HSA). Why, when and how? Surg Endosc 21:2224–2225

128. St Peter SD, Valusek PA, Calkins CM, Shew SB, Ostlie DJ, Holcomb GW III (2007) Use of esophagocrural sutures and minimal esophageal dissection reduces the incidence of postoperative transmigration of laparoscopic Nissen fundoplication wrap. J Pediatr Surg 42:25–29 (discussion 29–30)

129. Wykypiel H, Wetscher GJ, Klaus A, Schmid T, Gadenstaetter M, Bodner J, Bodner E (2003) Robot-assisted laparoscopic partial posterior fundoplication with the DaVinci system: initial experiences and technical aspects. Langenbecks Arch Surg 387:411–416

130. Muller-Stich BP, Reiter MA, Wente MN, Bintintan VV, Koninger J, Buchler MW, Gutt CN (2007) Robot-assisted versus conventional laparoscopic fundoplication: short-term outcome of a pilot randomized controlled trial. Surg Endosc 21:1800–1805

131. Draaisma WA, Ruurda JP, Scheffer RC, Simmermacher RK, Gooszen HG, Rijnhart-de Jong HG, Buskens E, Broeders IA (2006) Randomized clinical trial of standard laparoscopic versus robot-assisted laparoscopic Nissen fundoplication for gastro-oesophageal reflux disease. Br J Surg 93:1351–1359

132. Cadiere GB, Himpens J, Vertruyen M, Bruyns J, Germay O, Leman G, Izizaw R (2001) Evaluation of telesurgical (robotic) Nissen fundoplication. Surg Endosc 15:918–923

133. Nakadi IE, Melot C, Closset J, DeMoor V, Betroune K, Feron P, Lingier P, Gelin M (2006) Evaluation of da Vinci Nissen fundoplication clinical results and cost minimization. World J Surg 30:1050–1054

134. Stefanidis D, Wang F, Korndorffer JR, Jr, Dunne JB, Scott DJ (2010) Robotic assistance improves intracorporeal suturing performance and safety in the operating room while decreasing operator workload. Surg Endosc 24(2):377–382

135. El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR (2007) Obesity increases oesophageal acid exposure. Gut 56:749–755

136. Hampel H, Abraham NS, El-Serag HB (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199–211

137. Friedenberg FK, Xanthopoulos M, Foster GD, Richter JE (2008) The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol 103:2111–2122

138. El-Serag H (2008) The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci 53:2307–2312

139. El-Serag H (2008) Role of obesity in GORD-related disorders. Gut 57:281–284

140. Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P, Harvey R (2003) Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol 32:645–650

141. El-Serag HB, Graham DY, Satia JA, Rabeneck L (2005) Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 100:1243–1250

142. Fisichella PM, Patti MG (2009) Gastroesophageal reflux disease and morbid obesity: is there a relation? World J Surg 33(10):2034–2038

143. Morgenthal CB, Lin E, Shane MD, Hunter JG, Smith CD (2007) Who will fail laparoscopic Nissen fundoplication? Preoperative prediction of long-term outcomes. Surg Endosc 21:1978–1984

144. Perez AR, Moncure AC, Rattner DW (2001) Obesity adversely affects the outcome of antireflux operations. Surg Endosc 15:986–989

145. Ng VV, Booth MI, Stratford JJ, Jones L, Sohanpal J, Dehn TC (2007) Laparoscopic anti-reflux surgery is effective in obese patients with gastro-oesophageal reflux disease. Ann R Coll Surg Engl 89:696–702

146. Anvari M, Bamehriz F (2006) Outcome of laparoscopic Nissen fundoplication in patients with body mass index > or = 35. Surg Endosc 20:230–234

147. Fraser J, Watson DI, O'Boyle CJ, Jamieson GG (2001) Obesity and its effect on outcome of laparoscopic Nissen fundoplication. Dis Esophagus 14:50–53

148. D'Alessio MJ, Arnaoutakis D, Giarelli N, Villadolid DV, Rosemurgy AS (2005) Obesity is not a contraindication to laparoscopic Nissen fundoplication. J Gastrointest Surg 9:949–954

149. Kendrick ML, Houghton SG (2006) Gastroesophageal reflux disease in obese patients: the role of obesity in management. Dis Esophagus 19:57–63

150. Sise A, Friedenberg FK (2008) A comprehensive review of gastroesophageal reflux disease and obesity. Obes Rev 9: 194–203

151. Frezza EE, Ikramuddin S, Gourash W, Rakitt T, Kingston A, Luketich J, Schauer P (2002) Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc 16:1027–1031

152. Smith SC, Edwards CB, Goodman GN (1997) Symptomatic and clinical improvement in morbidly obese patients with gastroesophageal reflux disease following Roux-en-Y gastric bypass. Obes Surg 7:479–484

153. Patterson EJ, Davis DG, Khajanchee Y, Swanstrom LL (2003) Comparison of objective outcomes following laparoscopic Nissen fundoplication versus laparoscopic gastric bypass in the morbidly obese with heartburn. Surg Endosc 17:1561–1565

154. Raftopoulos I, Awais O, Courcoulas AP, Luketich JD (2004) Laparoscopic gastric bypass after antireflux surgery for the treatment of gastroesophageal reflux in morbidly obese patients: initial experience. Obes Surg 14:1373–1380

155. Varela JE, Hinojosa MW, Nguyen NT (2009) Laparoscopic fundoplication compared with laparoscopic gastric bypass in morbidly obese patients with gastroesophageal reflux disease. Surg Obes Relat Dis 5:139–143

156. Ikramuddin S (2008) Surgical management of gastroesophageal reflux disease in obesity. Dig Dis Sci 53:2318–2329

157. Perry Y, Courcoulas AP, Fernando HC, Buenaventura PO, McCaughan JS, Luketich JD (2004) Laparoscopic Roux-en-Y gastric bypass for recalcitrant gastroesophageal reflux disease in morbidly obese patients. JSLS 8:19–23

158. Forsell P, Hallerback B, Glise H, Hellers G (1999) Complications following Swedish adjustable gastric banding: a long-term follow-up. Obes Surg 9:11–16

159. Dixon JB, O'Brien PE (1999) Gastroesophageal reflux in obesity: the effect of lap-band placement. Obes Surg 9:527–531

160. Gutschow CA, Collet P, Prenzel K, Holscher AH, Schneider PM (2005) Long-term results and gastroesophageal reflux in a series of laparoscopic adjustable gastric banding. J Gastrointest Surg 9:941–948

161. Tolonen P, Victorzon M, Niemi R, Makela J (2006) Does gastric banding for morbid obesity reduce or increase gastroesophageal reflux? Obes Surg 16:1469–1474

162. Patterson EJ, Herron DM, Hansen PD, Ramzi N, Standage BA, Swanstrom LL (2000) Effect of an esophageal bougie on the incidence of dysphagia following Nissen fundoplication: a prospective, blinded, randomized clinical trial. Arch Surg 135:1055–1061 (discussion 1061–1052)

163. Kamolz T, Granderath FA, Pointner R (2003) The outcome of laparoscopic antireflux surgery in relation to patients' subjective degree of compliance with former antireflux medication. Surg Laparosc Endosc Percutan Tech 13:155–160

164. Pizza F, Rossetti G, Limongelli P, Del Genio G, Maffettone V, Napolitano V, Brusciano L, Russo G, Tolone S, Di Martino M, Del Genio A (2007) Influence of age on outcome of total laparoscopic fundoplication for gastroesophageal reflux disease. World J Gastroenterol 13:740–747

165. Iqbal A, Kakarlapudi GV, Awad ZT, Haynatzki G, Turaga KK, Karu A, Fritz K, Haider M, Mittal SK, Filipi CJ (2006) Assessment of diaphragmatic stressors as risk factors for symptomatic failure of laparoscopic Nissen fundoplication. J Gastrointest Surg 10:12–21

166. Kamolz T, Granderath FA, Pointner R (2003) Does major depression in patients with gastroesophageal reflux disease affect the outcome of laparoscopic antireflux surgery? Surg Endosc 17:55–60

167. Kamolz T, Granderath FA, Bammer T, Pasiut M, Pointner R (2001) Psychological intervention influences the outcome of laparoscopic antireflux surgery in patients with stress-related symptoms of gastroesophageal reflux disease. Scand J Gastroenterol 36:800–805

168. DeVault KR (2001) Gastroesophageal reflux disease: extra-esophageal manifestations and therapy. Semin Gastrointest Dis 12:46–51

169. Bresadola V, Dado G, Favero A, Terrosu G, Barriga Sainz M, Bresadola F (2006) Surgical therapy for patients with

extraesophageal symptoms of gastroesophageal reflux disease. Minerva Chir 61:9–15

170. del Genio G, Tolone S, del Genio F, Aggarwal R, d'Alessandro A, Allaria A, Rossetti G, Brusciano L, del Genio A (2008) Prospective assessment of patient selection for antireflux surgery by combined multichannel intraluminal impedance pH monitoring. J Gastrointest Surg 12:1491–1496

171. Allen CJ, Anvari M (2002) Preoperative symptom evaluation and esophageal acid infusion predict response to laparoscopic Nissen fundoplication in gastroesophageal reflux patients who present with cough. Surg Endosc 16:1037–1041

172. Patti MG, Perretta S, Fisichella PM, D'Avanzo A, Galvani C, Gorodner V, Way LW (2003) Laparoscopic antireflux surgery: preoperative lower esophageal sphincter pressure does not affect outcome. Surg Endosc 17:386–389

173. Cowgill SM, Bloomston M, Al-Saadi S, Villadolid D, Rosemurgy AS 2nd (2007) Normal lower esophageal sphincter pressure and length does not impact outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 11:701–707

174. Winslow ER, Clouse RE, Desai KM, Frisella P, Gunsberger T, Soper NJ, Klingensmith ME (2003) Influence of spastic motor disorders of the esophageal body on outcomes from laparoscopic antireflux surgery. Surg Endosc 17:738–745

175. Cowgill SM, Al-Saadi S, Villadolid D, Arnaoutakis D, Molloy D, Rosemurgy AS (2007) Upright, supine, or bipositional reflux: patterns of reflux do not affect outcome after laparoscopic Nissen fundoplication. Surg Endosc 21:2193–2198

176. Papasavas PK, Keenan RJ, Yeaney WW, Caushaj PF, Gagne DJ, Landreneau RJ (2003) Prediction of postoperative gas bloating after laparoscopic antireflux procedures based on 24-h pH acid reflux pattern. Surg Endosc 17:381–385

177. Wilkerson PM, Stratford J, Jones L, Sohanpal J, Booth MI, Dehn TC (2005) A poor response to proton pump inhibition is not a contraindication for laparoscopic antireflux surgery for gastro esophageal reflux disease. Surg Endosc 19:1272–1277

178. Byrne JP, Smithers BM, Nathanson LK, Martin I, Ong HS, Gotley DC (2005) Symptomatic and functional outcome after laparoscopic reoperation for failed antireflux surgery. Br J Surg 92:996–1001

179. Iqbal A, Awad Z, Simkins J, Shah R, Haider M, Salinas V, Turaga K, Karu A, Mittal SK, Filipi CJ (2006) Repair of 104 failed anti-reflux operations. Ann Surg 244:42–51

180. Oelschlager BK, Lal DR, Jensen E, Cahill M, Quiroga E, Pellegrini CA (2006) Medium- and long-term outcome of laparoscopic redo fundoplication. Surg Endosc 20:1817–1823

181. Khajanchee YS, O'Rourke R, Cassera MA, Gatta P, Hansen PD, Swanstrom LL (2007) Laparoscopic reintervention for failed antireflux surgery: subjective and objective outcomes in 176 consecutive patients. Arch Surg 142:785–901 (discussion 791–782)

182. Coelho JC, Goncalves CG, Claus CM, Andrigueto PC, Ribeiro MN (2004) Late laparoscopic reoperation of failed antireflux procedures. Surg Laparosc Endosc Percutan Tech 14:113–117

183. Cowgill SM, Arnaoutakis D, Villadolid D, Rosemurgy AS (2007) "Redo" fundoplications: satisfactory symptomatic outcomes with higher cost of care. J Surg Res 143:183–188

184. Curet MJ, Josloff RK, Schoeb O, Zucker KA (1999) Laparoscopic reoperation for failed antireflux procedures. Arch Surg 134:559–563

185. Floch NR, Hinder RA, Klingler PJ, Branton SA, Seelig MH, Bammer T, Filipi CJ (1999) Is laparoscopic reoperation for failed antireflux surgery feasible? Arch Surg 134:733–737

186. Ohnmacht GA, Deschamps C, Cassivi SD, Nichols FC III, Allen MS, Schleck CD, Pairolero PC (2006) Failed antireflux surgery: results after reoperation. Ann Thorac Surg 81:2050–2053 (discussion 2053–2054)

187. Szwerc MF, Wiechmann RJ, Maley RH, Santucci TS, Macherey RS, Landreneau RJ (1999) Reoperative laparoscopic antireflux surgery. Surgery 126:723–728 (discussion 728–729)

188. Cowgill SM, Gillman R, Kraemer E, Al-Saadi S, Villadolid D, Rosemurgy A (2007) Ten-year follow up after laparoscopic Nissen fundoplication for gastroesophageal reflux disease. Am Surg 73:748–752 (discussion 752–743)

189. Zeman Z, Tihanyi T (2007) Quality of life and patient satisfaction after laparoscopic antireflux surgery using the QOLARS questionnaire. Surg Endosc 21:1418–1422

190. Kaufman JA, Houghland JE, Quiroga E, Cahill M, Pellegrini CA, Oelschlager BK (2006) Long-term outcomes of laparoscopic antireflux surgery for gastroesophageal reflux disease (GERD)-related airway disorder. Surg Endosc 20:1824–1830

191. Balci D, Turkcapar AG (2007) Assessment of quality of life after laparoscopic Nissen fundoplication in patients with gastroesophageal reflux disease. World J Surg 31:116–121

192. Neumayer C, Ciovica R, Gadenstatter M, Erd G, Leidl S, Lehr S, Schwab G (2005) Significant weight loss after laparoscopic Nissen fundoplication. Surg Endosc 19:15–20

193. Ciovica R, Gadenstatter M, Klingler A, Neumayer C, Schwab GP (2005) Laparoscopic antireflux surgery provides excellent results and quality of life in gastroesophageal reflux disease patients with respiratory symptoms. J Gastrointest Surg 9:633–637

194. Biertho L, Sebajang H, Allen C, Anvari M (2006) Does laparoscopic Nissen fundoplication lead to chronic gastrointestinal dysfunction? Surg Endosc 20:1360–1363

195. Tedesco P, Lobo E, Fisichella PM, Way LW, Patti MG (2006) Laparoscopic fundoplication in elderly patients with gastroesophageal reflux disease. Arch Surg 141:289–292 (discussion 292)

196. Zacharoulis D, O'Boyle CJ, Sedman PC, Brough WA, Royston CM (2006) Laparoscopic fundoplication: a 10-year learning curve. Surg Endosc 20:1662–1670

197. Mark LA, Okrainec A, Ferri LE, Feldman LS, Mayrand S, Fried GM (2008) Comparison of patient-centered outcomes after laparoscopic Nissen fundoplication for gastroesophageal reflux disease or paraesophageal hernia. Surg Endosc 22:343–347

198. Papasavas PK, Keenan RJ, Yeaney WW, Caushaj PF, Gagne DJ, Landreneau RJ (2003) Effectiveness of laparoscopic fundoplication in relieving the symptoms of gastroesophageal reflux disease (GERD) and eliminating antireflux medical therapy. Surg Endosc 17:1200–1205

199. Vidal O, Lacy AM, Pera M, Valentini M, Bollo J, Lacima G, Grande L (2006) Long-term control of gastroesophageal reflux disease symptoms after laparoscopic Nissen–Rosetti fundoplication. J Gastrointest Surg 10:863–869

200. Desai KM, Soper NJ, Frisella MM, Quasebarth MA, Dunnegan DL, Brunt LM (2003) Efficacy of laparoscopic antireflux surgery in patients with Barrett's esophagus. Am J Surg 186:652–659

201. Desai KM, Frisella MM, Soper NJ (2003) Clinical outcomes after laparoscopic antireflux surgery in patients with and without preoperative endoscopic esophagitis. J Gastrointest Surg 7:44–51 (discussion 51–42)

202. Fernando HC, El-Sherif A, Landreneau RJ, Gilbert S, Christie NA, Buenaventura PO, Close JM, Luketich JD (2005) Efficacy of laparoscopic fundoplication in controlling pulmonary symptoms associated with gastroesophageal reflux disease. Surgery 138:612–616 (discussion 616–617)

203. Mehta S, Hindmarsh A, Rhodes M (2005) Changes in functional gastrointestinal symptoms as a result of antireflux surgery. Surg Endosc 19:1447–1450

204. Bloomston M, Nields W, Rosemurgy AS (2003) Symptoms and antireflux medication use following laparoscopic Nissen fundoplication: outcome at 1 and 4 years. JSLS 7:211–218

205. Huttl TP, Hohle M, Wichmann MW, Jauch KW, Meyer G (2005) Techniques and results of laparoscopic antireflux surgery in Germany. Surg Endosc 19:1579–1587

206. Brouwer R, Kiroff GK (2003) Improvement of respiratory symptoms following laparoscopic Nissen fundoplication. ANZ J Surg 73:189–193

207. Triponez F, Dumonceau JM, Azagury D, Volonte F, Slim K, Mermillod B, Huber O, Morel P (2005) Reflux, dysphagia, and gas bloat after laparoscopic fundoplication in patients with incidentally discovered hiatal hernia and in a control group. Surgery 137:235–242

208. Menon VS, Manson JM, Baxter JN (2003) Laparoscopic fundoplication: learning curve and patient satisfaction. Ann R Coll Surg Engl 85:10–13

209. Duffy JP, Maggard M, Hiyama DT, Atkinson JB, McFadden DW, Ko CY, Hines OJ (2003) Laparoscopic Nissen fundoplication improves quality of life in patients with atypical symptoms of gastroesophageal reflux. Am Surg 69:833–838

210. Ozmen V, Oran ES, Gorgun E, Asoglu O, Igci A, Kecer M, Dizdaroglu F (2006) Histologic and clinical outcome after laparoscopic Nissen fundoplication for gastroesophageal reflux disease and Barrett's esophagus. Surg Endosc 20:226–229

211. Liu JY, Woloshin S, Laycock WS, Schwartz LM (2002) Late outcomes after laparoscopic surgery for gastroesophageal reflux. Arch Surg 137:397–401

212. Salminen PT, Laine SO, Ovaska JT (2006) Late subjective results and symptomatic outcome after laparoscopic fundoplication. Surg Laparosc Endosc Percutan Tech 16:203–207

213. Kamolz T, Granderath F, Pointner R (2003) Laparoscopic antireflux surgery: disease-related quality of life assessment before and after surgery in GERD patients with and without Barrett's esophagus. Surg Endosc 17:880–885

214. Fernando HC, Schauer PR, Buenaventura PO, Christie NA, Close JM, Luketich JD (2003) Outcomes of minimally invasive antireflux operations in the elderly: a comparative review. JSLS 7:311–315

215. Pitcher DE, Curet MJ, Martin DT, Castillo RR, Gerstenberger PD, Vogt D, Zucker KA (1994) Successful management of severe gastroesophageal reflux disease with laparoscopic Nissen fundoplication. Am J Surg 168:547–553 (discussion 553–544)

216. Abbas AE, Deschamps C, Cassivi SD, Allen MS, Nichols FC 3rd, Miller DL, Pairolero PC (2004) Barrett's esophagus: the role of laparoscopic fundoplication. Ann Thorac Surg 77: 393–396

217. Wetscher GJ, Glaser K, Gadenstatter M, Wieschemeyer T, Profanter C, Klinger P (1998) Laparoscopic partial posterior fundoplication improves poor oesophageal contractility in patients with gastrooesophageal reflux disease. Eur J Surg 164:679–684

218. Popiela T, Kawiorski W, Richter P, Legutko J, Kibil W (2005) Late complications after antireflux procedures using intraoperative continuous computer-video manometry monitoring. Acta Chir Belg 105:275–282

219. Hunter JG, Smith CD, Branum GD, Waring JP, Trus TL, Cornwell M, Galloway K (1999) Laparoscopic fundoplication failures: patterns of failure and response to fundoplication revision. Ann Surg 230:595–604 (discussion 604–596)

220. Champault GG, Barrat C, Rozon RC, Rizk N, Catheline JM (1999) The effect of the learning curve on the outcome of laparoscopic treatment for gastroesophageal reflux. Surg Laparosc Endosc Percutan Tech 9:375–381

221. Kiviluoto T, Siren J, Farkkila M, Luukkonen P, Salo J, Kivilaakso E (1998) Laparoscopic Nissen fundoplication: a prospective analysis of 200 consecutive patients. Surg Laparosc Endosc 8:429–434

222. Brehant O, Pessaux P, Arnaud JP, Delattre JF, Meyer C, Baulieux J, Mosnier H (2006) Long-term outcome of laparoscopic antireflux surgery in the elderly. J Gastrointest Surg 10:439–444

223. Allen CJ, Anvari M (2004) Does laparoscopic fundoplication provide long-term control of gastroesophageal reflux related cough? Surg Endosc 18:633–637

224. Anvari M, Allen C (2003) Surgical outcome in gastro-esophageal reflux disease patients with inadequate response to proton pump inhibitors. Surg Endosc 17:1029–1035

225. Cuschieri A, Hunter J, Wolfe B, Swanstrom LL, Hutson W (1993) Multicenter prospective evaluation of laparoscopic antireflux surgery. Preliminary report. Surg Endosc 7:505–510

226. Allen CJ, Anvari M (1998) Gastro-oesophageal reflux related cough and its response to laparoscopic fundoplication. Thorax 53:963–968

227. Granderath FA, Granderath UM, Pointner R (2008) Laparoscopic revisional fundoplication with circular hiatal mesh prosthesis: the long-term results. World J Surg 32:999–1007

228. Hong D, Swanstrom LL, Khajanchee YS, Pereira N, Hansen PD (2004) Postoperative objective outcomes for upright, supine, and bipositional reflux disease following laparoscopic Nissen fundoplication. Arch Surg 139:848–852 (discussion 852–844)

229. Swoger J, Ponsky J, Hicks DM, Richter JE, Abelson TI, Milstein C, Qadeer MA, Vaezi MF (2006) Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 4: 433–441

230. Hinder RA, Filipi CJ, Wetscher G, Neary P, DeMeester TR, Perdikis G (1994) Laparoscopic Nissen fundoplication is an effective treatment for gastroesophageal reflux disease. Ann Surg 220:472–481 (discussion 481–473)

231. Lindeboom MY, Ringers J, van Rijn PJ, Neijenhuis P, Stokkel MP, Masclee AA (2004) Gastric emptying and vagus nerve function after laparoscopic partial fundoplication. Ann Surg 240:785–790

232. Ogut F, Ersin S, Engin EZ, Kirazli T, Midilli R, Unsal G, Bor S (2007) The effect of laparoscopic Nissen fundoplication on laryngeal findings and voice quality. Surg Endosc 21:549–554

233. Granderath FA, Schweiger UM, Pointner R (2007) Laparoscopic antireflux surgery: tailoring the hiatal closure to the size of hiatal surface area. Surg Endosc 21:542–548

234. el-Sherif AE, Adusumilli PS, Pettiford BL, d'Amato TA, Schuchert MJ, Clark A, DiRenzo C, Landreneau JP, Luketich JD, Landreneau RJ (2007) Laparoscopic clam shell partial fundoplication achieves effective reflux control with reduced postoperative dysphagia and gas bloating. Ann Thorac Surg 84:1704–1709

235. del Genio G, Rossetti G, Brusciano L, Limongelli P, Pizza F, Tolone S, Fei L, Maffettone V, Napolitano V, del Genio A (2007) Laparoscopic Nissen–Rossetti fundoplication with routine use of intraoperative endoscopy and manometry: technical aspects of a standardized technique. World J Surg 31:1099–1106

236. El Nakadi I, Closset J, De Moor V, Coppens E, Zalcman M, Deviere J, Gelin M (2004) Laparoscopic Nissen fundoplication after failure of Enteryx injection into the lower esophageal sphincter. Surg Endosc 18:818–820

237. Champion JK (2003) Thoracoscopic Belsey fundoplication with 5-year outcomes. Surg Endosc 17:1212–1215

238. Glaser K, Wetscher GJ, Klingler A, Klingler PJ, Eltschka B, Hollinsky C, Achem SR, Hinder RA (2000) Selection of patients for laparoscopic antireflux surgery. Dig Dis 18:129–137

239. Tucker JG, Ramshaw BJ, Newman CL, Sims MS, Mason EM, Duncan TD, Lucas GW (1996) Laparoscopic fundoplication in the treatment of severe gastroesophageal reflux disease: preliminary results of a prospective trial. South Med J 89:60–64

240. Khajanchee YS, Hong D, Hansen PD, Swanstrom LL (2004) Outcomes of antireflux surgery in patients with normal preoperative 24-hour pH test results. Am J Surg 187:599–603

241. Neuhauser B, Hinder RA (2001) Laparoscopic reoperation after failed antireflux surgery. Semin Laparosc Surg 8:281–286

242. Walsh JD, Landercasper J, Boyd WC, Lambert PJ, Havlik PJ (2003) Patient outcomes and dysphagia after laparoscopic anti-reflux surgery performed without use of intraoperative esopha-geal dilators. Am Surg 69:219–223 discussion 223-214

243. Nguyen NT, Schauer PR, Hutson W, Landreneau R, Weigel T, Ferson PF, Keenan RJ, Luketich JD (1998) Preliminary results of thoracoscopic Belsey mark IV antireflux procedure. Surg Laparosc Endosc 8:185–188

244. Bonatti H, Bammer T, Achem SR, Lukens F, DeVault KR, Klaus A, Hinder RA (2007) Use of acid suppressive medications after laparoscopic antireflux surgery: prevalence and clinical indications. Dig Dis Sci 52:267–272

245. Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287:1972–1981

246. Reid BJ (1991) Barrett's esophagus and esophageal adenocar-cinoma. Gastroenterol Clin North Am 20:817–834

247. Peters JH, Hagen JA, DeMeester SR (2004) Barrett's esophagus. J Gastrointest Surg 8:1–17

248. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, Cameron A, Corley D, Falk G, Goldblum J, Hunter J, Jankowski J, Lundell L, Reid B, Shaheen NJ, Sonnenberg A, Wang K, Weinstein W (2004) A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 127:310–330

249. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agreus L (2005) Prevalence of Barrett's esophagus in the general popu-lation: an endoscopic study. Gastroenterology 129:1825–1831

250. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, Dunne D, Rahmani EY, Helper DJ (2003) Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125:1670–1677

251. Attwood SE, Lundell L, Hatlebakk JG, Eklund S, Junghard O, Galmiche JP, Ell C, Fiocca R, Lind T (2008) Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg 12:1646–1654 (discussion 1654–1645)

252. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sam-pliner RE (2006) Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 4:566–572

253. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS (2000) Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119:333–338

254. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR (2000) The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 95:3383–3387

255. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ (2001) Extent of high-grade dysplasia in Barrett's esophagus corre-lates with risk of adenocarcinoma. Gastroenterology 120:1630–1639

256. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Bar-rett's oesophagus: a prospective study. Lancet Oncol 6:945–952

257. Wang KK, Sampliner RE (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103:788–797

258. Odze RD (2006) Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol 59:1029–1038

259. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H (1978) Adeno-carcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 70:1–5

260. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K (2001) Reproducibility of the diagnosis of dysplasia in Barrett esoph-agus: a reaffirmation. Hum Pathol 32:368–378

261. Oh DS, Hagen JA, Chandrasoma PT, Dunst CM, Demeester SR, Alavi M, Bremner CG, Lipham J, Rizzetto C, Cote R, Deme-ester TR (2006) Clinical biology and surgical therapy of intra-mucosal adenocarcinoma of the esophagus. J Am Coll Surg 203:152–161

262. Nguyen NT, Schauer P, Luketich JD (2000) Minimally invasive esophagectomy for Barrett's esophagus with high-grade dys-plasia. Surgery 127:284–290

263. Luketich JD, Landreneau RJ (2004) Minimally invasive resec-tion and mechanical cervical esophagogastric anastomotic techniques in the management of esophageal cancer. J Gastro-intest Surg 8:927–929

264. Prasad GA, Wang KK, Buttar NS, Wongkeesong LM, Krish-nadath KK, Nichols FC 3rd, Lutzke LS, Borkenhagen LS (2007) Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterol-ogy 132:1226–1233

265. Prasad GA, Wu TT, Wigle DA, Buttar NS, Wongkeesong LM, Dunagan KT, Lutzke LS, Borkenhagen LS, Wang KK (2009) Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 137:815–823

266. Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, Bronner MP, Taylor SL, Grace MG, Depot M (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62:488–498

267. Pech O, Gossner L, May A, Rabenstein T, Vieth M, Stolte M, Berres M, Ell C (2005) Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 62:24–30

268. May A, Gossner L, Behrens A, Kohnen R, Vieth M, Stolte M, Ell C (2003) A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc 58:167–175

269. Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, Henrich R, Vieth M, Muller H, Seitz G, Stolte M (2000) Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 118:670–677

270. Seewald S, Akaraviputh T, Seitz U, Brand B, Groth S, Mendoza G, He X, Thonke F, Stolte M, Schroeder S, Soehendra N (2003) Circumferential EMR and complete removal of Barrett's epi-thelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 57:854–859

271. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Hari-ngsma J, van de Vrie W, Grool TE, van Veen RL, Sterenborg HJ, Kuipers EJ (2004) 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Bar-rett's oesophagus: a randomised trial. Gut 53:785–790

272. Sharma P, Wani S, Weston AP, Bansal A, Hall M, Mathur S, Prasad A, Sampliner RE (2006) A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut 55:1233–1239

273. Tigges H, Fuchs KH, Maroske J, Fein M, Freys SM, Muller J, Thiede A (2001) Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus. J Gastrointest Surg 5:251–259

274. Morino M, Rebecchi F, Giaccone C, Taraglio S, Sidoli L, Ferraris R (2003) Endoscopic ablation of Barrett's esophagus using argon plasma coagulation (APC) following surgical laparoscopic fundoplication. Surg Endosc 17:539–542

275. Dulai GS, Jensen DM, Cortina G, Fontana L, Ippoliti A (2005) Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc 61:232–240

276. Montes CG, Brandalise NA, Deliza R, Novais de Magalhaes AF, Ferraz JG (1999) Antireflux surgery followed by bipolar electrocoagulation in the treatment of Barrett's esophagus. Gastrointest Endosc 50:173–177

277. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ (2009) Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 360:2277–2288

278. Sharma VK, Wang KK, Overholt BF, Lightdale CJ, Fennerty MB, Dean PJ, Pleskow DK, Chuttani R, Reymunde A, Santiago N, Chang KJ, Kimmey MB, Fleischer DE (2007) Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 65:185–195

279. Sharma VK, Kim HJ, Das A, Dean P, DePetris G, Fleischer DE (2008) A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy 40:380–387

280. Pouw RE, Wirths K, Eisendrath P, Sondermeijer CM, Kate FJ, Fockens P, Deviere J, Neuhaus H, Bergman JJ (2010) Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 8(1):23–29

281. Velanovich V (2009) Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus: initial results and lessons learned. Surg Endosc 23:2175–2180

282. Sharma VK, Jae Kim H, Das A, Wells CD, Nguyen CC, Fleischer DE (2009) Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol 104:310–317

283. Fleischer DE, Overholt BF, Sharma VK, Reymunde A, Kimmey MB, Chuttani R, Chang KJ, Lightdale CJ, Santiago N, Pleskow DK, Dean PJ, Wang KK (2008) Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 68:867–876

284. Pouw RE, Gondrie JJ, Sondermeijer CM, ten Kate FJ, van Gulik TM, Krishnadath KK, Fockens P, Weusten BL, Bergman JJ (2008) Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg 12:1627–1636 (discussion 1636–1627)

285. Ganz RA, Overholt BF, Sharma VK, Fleischer DE, Shaheen NJ, Lightdale CJ, Freeman SR, Pruitt RE, Urayama SM, Gress F, Pavey DA, Branch MS, Savides TJ, Chang KJ, Muthusamy VR, Bohorfoush AG, Pace SC, DeMeester SR, Eysselein VE, Panjehpour M, Triadafilopoulos G (2008) Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 68:35–40

286. Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD (2004) Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 60:739–756

287. Pohl H, Sonnenberg A, Strobel S, Eckardt A, Rosch T (2009) Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis. Gastrointest Endosc 70:623–634

288. Das A, Wells C, Kim HJ, Fleischer DE, Crowell MD, Sharma VK (2009) An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus. Endoscopy 41:400–408

289. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ (2009) A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 136:2101–2114 (e2101–2106)

290. Faybush EM, Sampliner RE (2005) Randomized trials in the treatment of Barrett's esophagus. Dis Esophagus 18:291–297

291. Parrilla P, Martinez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, Canteras M (2003) Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 237:291–298

292. Oberg S, Johansson J, Wenner J, Johnsson F, Zilling T, von Holstein CS, Nilsson J, Walther B (2001) Endoscopic surveillance of columnar-lined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg 234:619–626

293. Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, DeMeester SR, Crookes PF, Tsai P, Banki F, Bremner CG (2001) Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 234:532–538 (discussion 538–539)